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Human herpesvirus 8 (HHV-8) is a lymphotropic gammaherpesvirus that causes Kaposi's 
sarcoma (KS), a vascular tumor of spindle-shaped endothelial cells.  The importance of 
determining effective prevention and treatment for HHV-8 infection is evident in that KS 
continues to be the most common cancer among HIV-1 and AIDS patients.  It is postulated that 
CD8+ T cell responses play an important role in controlling HHV-8 infection and preventing KS.  
However, there are minimal data supporting the role for T cell immunity in control of HHV-8 
infection.  Therefore, I investigated CD8+ T cell responses to HHV-8 lytic and latency proteins. 
I used our dendritic cell-based system in an IFN-γ ELISPOT to identify novel epitopes in 
healthy, HHV-8 seropositive individuals, then further assessed new epitopes for immune 
mediators using polychromatic flow cytometry.  I also used multimer complexes to directly 
detect HHV-8-specific CD8+ T cells in blood.  I investigated the effect of regulatory T cells 
(Treg) on these anti-HHV-8 T cell responses by depleting samples of Treg.  I then applied these 
assays to patients in the Multicenter AIDS Cohort Study to longitudinally investigate the role of 
these responses during the progression to KS.   
Through these studies, I identified 10 novel HLA A*0201-restricted epitopes, which 
activated both monofunctional and polyfunctional CD8+ T cells producing various combinations 
of immune mediators.  Responses were lower over many years prior to development of KS.  
Although CD8+ T cell IFN-γ responses were modest, a low but consistent percent of HHV-8-
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specific CD8+ T cells were present in blood, suggesting a functional down-regulation of this 
response.  In support of this, removal of Treg enhanced CD8+ T cell responses to HHV-8 
epitopes, and numbers of Treg increased prior to KS development.   
Overall, these data support that T cell responses, in frequency, magnitude and quality, are 
essential for the control of HHV-8 infection to prevent disease development.  They also indicate 
that these antiviral T cell responses are in part controlled by Treg.  Involvement of CD8+ T cells 
and Treg in control of HHV-8 infection has public health significance through implications for 
understanding the immunopathogenesis of HHV-8 needed for prevention and treatment of KS. 
 vi 
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1.0  HUMAN HERPESVIRUS 8 INTRODUCTION 
Human herpesvirus 8 (HHV-8), or Kaposi’s sarcoma associated herpesvirus (KSHV), is the 
etiologic agent of Kaposi’s sarcoma (KS) (42), a neoplasm of endothelial origin that occurs in 
four distinct epidemiologic forms (57, 113): classic or Mediterranean KS, epidemic or acquired 
immune deficiency syndrome (AIDS)-related KS, endemic or African KS, and iatrogenic or 
organ transplant-associated KS.  KS is the most common cancer associated with human 
immunodeficiency virus 1 (HIV-1) infection and AIDS (48).  Although the incidence of KS in 
HIV-1 infected persons declined with the advent of antiretroviral therapy (ART) (81), KS can 
occur in persons on ART with suppressed HIV-1 infection (159).  The success of ART in 
treating HIV-1 associated KS has been countered by the occasional occurrence of an immune 
reconstitution inflammatory syndrome (73).  This is a severe, temporary enhancement of KS 
lesions due to an increase in inflammation and immunologic recovery after ART.   
The discovery of HHV-8 and its causal role in KS development opened the potential for 
prophylaxis and treatment of the infection and cancer with antiviral drugs, and prevention of 
both with a vaccine.  Strategies to achieve these ends require an intimate knowledge of the 
pathogenesis and immune control of HHV-8 infection.   It is likely that host control of HHV-8 
infection and development of KS is linked to T cell interactions with HHV-8 infected, 
professional antigen presenting cells (APC), i.e., dendritic cells (DC), monocytes/macrophages 
and B lymphocytes.  Similarly, APC-T interactions are likely to be centrally involved in the 
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HHV-8 associated B cell neoplasms multicentric Castleman’s Disease (MCD) (218) and primary 
effusion lymphoma (PEL) (35, 171).  
HHV-8 has been reported to be transmitted to common marmosets and cause persistent 
infection with rare, KS-like skin lesions (41).  However, there is as yet no consensus that this or 
other simian models (74, 115, 203) recapitulate human HHV-8 infection and development of KS 
or other cancers associated with this herpesvirus.  Thus, although in vitro models are suspect to 
lacking certain in vivo characteristics, they are currently the best model of HHV-8 infection. 
1.1 HHV-8 INFECTION OF PROFESSIONAL APC 
As with the other human gammaherpesvirus, Epstein Barr virus (EBV) (179), HHV-8 targets 
APC both in vivo and in vitro.  Indeed, the primary tropism of B cells by these 
gammaherpesviruses is uncommon among human virus infections.  This sets the stage for 
development of their associated cancers both indirectly through alteration of host immunity 
dependent on APC function, and directly via neoplastic effects of the virus.  HHV-8 is found in 
KS spindle cells, which are of mixed vascular and lymphatic endothelial cell and macrophage 
origin, monocytes that are found in proximity to KS lesions, and circulating B cells of KS 
patients (24, 30, 166, 194).  In PEL, HHV-8 is found in immunoblastic cells expressing plasma 
cell markers, and in plasmablastic cells of a less terminally differentiated state in MCD (62).  
The intimate association of HHV-8 with such professional APC in the KS lesion and in other 
HHV-8 associated cancers suggests a major role for virus-APC interplay.  Moreover, anti-HHV-
8 T cell immunity, that presumably is critically dependent on such virus-APC interactions, is 
present in HIV-1 infected and uninfected persons who are seropositive for HHV-8 (202).  
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Achieving a better understanding of the role of HHV-8 in inducing associated cancers could 
greatly benefit from a yet-to-be-developed in vitro model of primary HHV-8 infection of a 
natural target cell that consistently reflects virus lytic, latent and reactivation infections.  HHV-8 
infection of APC could provide such a model.  
1.1.1 HHV-8 receptors on APC 
Infection of APC in vitro reveals different cycles of HHV-8 replication that are likely to relate to 
the pathogenesis of the virus.  The first step in targeting and alteration of APC by HHV-8 is at 
the level of cell receptor.  Herpesviruses use more than one receptor to infect the same cell (100).  
Use of these receptors by herpesviruses is hierarchical based largely on differential expression of 
the receptors in specific cell types and states of cell activation.  Extensive in vitro evidence 
indicates that the ubiquitous cell surface proteoglycan heparan sulfate serves as an initial binding 
receptor for HHV-8 on endothelial cells and fibroblasts as well as APC (4, 5, 39, 119).  Multiple 
integrins are subsequently involved in HHV-8 binding and entry (119).  A third level of 
differential selection that has been identified from in vitro studies of the three major types of 
APC, i.e., monocyte-derived DC (MDDC), B cells and monocyte-derived macrophages (MDM), 
is the type II C-type lectin, DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN; CD209) (191, 
192).  A new entry receptor for HHV-8 on endothelial and epithelial cells (95), i.e., ephrin 
receptor tyrosine kinase A2, a tyrosine kinase that functions in neovascularization and 
oncogenesis, has not yet been assessed in HHV-8 infection of APC.  
The relative contribution of each level of HHV-8 binding to viral infection of APC is not 
clear.  For example, the Raji B lymphoblastoid cell line (LCL) and the myeloblastoid K562 cell 
line constitutively express little or no DC-SIGN or α3β1 integrin (192).  Thus, these cell lines do 
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not support detectable production of infectious virions (13, 23, 192).  However, transfection of 
the cell lines with DC-SIGN renders them highly permissive for HHV-8 infection as measured 
by the production of viral proteins and DNA (192).  Moreover, infection of these cell lines can 
be blocked by anti-DC-SIGN monoclonal antibody (mAb), soluble DC-SIGN and mannan, a 
natural ligand of DC-SIGN.  Interestingly, six B cell and T cell lines (BLAB, Ramos, BCBL-1, 
JSC1, Jurkat and SupT1) were susceptible to infection through cell-mediated transmission with a 
doxycycline (Dox)- inducible cell line harboring recombinant HHV-8 (rKSHV.219), indicating 
that viral entry can be achieved despite lack of expression of a major HHV-8 receptor (170).  
There is also evidence that HHV-8 can infect CD34+ stem cell precursors of DC in vitro by as 
yet undefined receptors (101, 131).  It is likely that there are less prominent alternative receptors 
for HHV-8 that account for a small percentage of DC-SIGN negative APC and cell lines that can 
be infected by this virus. 
1.1.2 B cell infection with HHV-8 
Suggestive evidence that HHV-8 is B-cell tropic in vivo is that HHV-8 DNA is detected in B 
cells from patients with KS lesions (6) and some HIV-1/HHV-8 co-infected individuals (156).  It 
is likely that this is related to DC-SIGN expression that is enhanced by an activated state in B 
cells.  In support of this, previous work from our laboratory showed that once blood-derived B 
cells are activated to express DC-SIGN, HHV-8 can effectively establish infection and elicit full-
cycle production of infectious virions in these cells (191).  The fact that HHV-8 cannot infect 
Raji LCL and the K562 erythroleukemia cell line expressing DC-SIGN that lacks the 
transmembrane domain supports DC-SIGN-mediated endocytosis of viral entry.  Moreover, 
infection can be blocked by pretreatment of the B cells with anti-DC-SIGN mAb or mannan, but 
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not an antibody specific for the amino acid transporter protein xCT (191).  HHV-8 has been 
reported to use xCT for infection of surface adherent human cells (116),  and in a post-entry 
stage of human endothelial cell infection as part of a complex of heterodimeric membrane 
glycoprotein CD98 and the α3β1 and αVβ3 integrins (239).  Notably, HHV-8 infection is not 
restricted to blood-derived B cells, as tonsillar B cells constitutively express DC-SIGN and can 
be lytically infected with the virus in vitro (168, 191).  It is probable that B cells in such tonsillar 
tissue are in an endogenously activated state resulting in enhanced expression of DC-SIGN.  
HHV-8 infection of freshly derived blood and tissue B lymphocytes could provide an in 
vitro model for assessing HHV-8 lytic and latent infection.  Our in vitro model for measuring 
HHV-8 infectivity and replication supports the concept previously put forth that DC-SIGN is a 
major receptor for this virus (39, 191, 192).  This adds to the wealth of evidence that shows that 
in addition to certain integrins (3-5, 21, 239), DC-SIGN is required for highly efficient infection 
of the natural APC targets with HHV-8, which is in contrast to previous reports (84).  However, 
there is still need for improved reliable, quantitative measures of HHV-8 replication to better 
define B cell infection with HHV-8.  These measures should include combinations of real-time 
polymerase chain reaction (PCR) assays for cell-associated and non-cell associated copy 
numbers of HHV-8 encapsidated DNA, flow cytometry assays for the enumerating the number 
of mAb-stained cells expressing viral lytic and latency cycle proteins, and most important, cell 
culture-based assays, e.g., a 50% tissue culture infectious dose assay, for quantitating the number 
of infectious virus particles.  
It is postulated that HHV-8 infection drives B cells to an early plasmablast-like state in 
MCD and a pre-terminal plasma cell stage of differentiation in PEL (2, 35-37, 63, 64, 80, 98, 
123, 157, 164, 172).  Hassman et al., recently showed that latency associated nuclear antigen 
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(LANA, encoded by ORF73)-positive B cells express immunoglobulin (Ig) M and the λ light 
chain at 2.5-3.5 days post-HHV-8 infection.  These cells are plasmablast-like with increased 
interleukin (IL)-6R expression and increased proliferative response to IL-6, with 7-36% 
expressing CD27 (98).  This molecule is a member of the tumor necrosis factor (TNF)-receptor 
superfamily, and is involved in regulation of B cell activation.  It is not known whether HHV-8 
directly infects these IgM+ memory B cells or a precursor of these cells.  Also, there are no data 
on which subset of B cells supports a complete lytic cycle of replication with virion formation 
and death of the cell, or if this is abortive, leaving HHV-8 infected memory B cells that survive 
and maintain latent virus infection.  It is possible that the infection of naïve and IgM+ memory B 
cells leads to establishment of latency in a portion of cells, resulting in virus-driven plasmablast 
differentiation, while some cells support the viral lytic cycle.  Activated B cells may support full 
lytic cycle replication, resulting in virion formation and cell lysis, or HHV-8 could abort the 
cycle prematurely and either enter latency or result in cell apoptosis.  
Such definitive B cell targets for primary infection and lytic replication could be useful in 
studies of HHV-8 prophylactic and therapeutic vaccines.  Currently, the main in vitro models to 
recapitulate HHV-8 infection in APC are cell lines persistently infected with the virus, 
particularly body cavity based lymphoma cells (BCBL)-1, a B cell line derived from PEL, which 
is latently infected with HHV-8 and EBV negative (35, 42).  In such cell line models, HHV-8 
lytic and latent infections cannot be defined conventionally starting with the total absence of 
infectious viral particles, as there is always a low level of persistent virus production.  However, 
latency can be disrupted, triggering the lytic cascade of viral replication and lytic genes 
expressed sequentially as immediate early genes, early genes and late genes, resulting in 
production of encapsidated virions.  Such lytic viral replication is largely irreversible (39, 247).  
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HHV-8 lytic gene profiling in these models has been extensively accomplished using tiling 
microarray (43), DNA microarray (2, 40, 147), and high-throughput real-time PCR (60, 71).  
However, most studies on latency-lytic reactivation of HHV-8 use various chemicals to induce 
viral replication (169).  The question is whether such reactivation reflects natural HHV-8 viral 
lytic reactivation from latency, since chemical agents such as 12-O-tetradecanoylphorbol-13-
acetate (TPA) have pleiotropic effects on host cell signaling and chromatin structure.  How they 
affect cell signaling pathways is also unknown.  Thus, the natural reactivated cascade of lytic 
transcripts of HHV-8 still waits to be revealed.   
Instead of using chemical inducers, Nakamura et al. (173) developed an engineered 
BCBL-1 cell line that inducibly expresses the replication transactivator protein, RTA, encoded 
by open reading frame (ORF) 50, i.e., TREx-BCBL1-RTA.  RTA has been shown to be 
necessary and sufficient for the switch between HHV-8 latency and lytic replication (59).  In 
fact, mutation of the RBP-Jk sites within the RTA promoter is enough to enhance latency in 
transformed-293 cells and peripheral blood mononuclear cells (PBMC) (150).  In  the TREx-
BCBL1-RTA cell line, RTA expression is under the control of a Dox-inducible promoter and 
treatment of TREx-BCBL1-RTA cells with Dox results in expression of RTA, which in turn 
induces viral replication (173).  While the role of RTA in causing a switch from latency to viral 
replication has been demonstrated by several laboratories, the mechanisms regulating coordinate 
induction of expression of most of the HHV-8 lytic genes during this reactivation have not been 
evaluated in a systematic fashion. 
Transcription of HHV-8 lytic genes occurs during either a primary infection of 
susceptible cells or during reactivation of latently infected cells.  The question remains whether 
the kinetic gene activation in a chemically induced cell line (BCBL-1) or the naturally targeted 
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RTA (TREx-BCBL1-RTA) will reflect the cascade events of a natural infection of B cells or 
other APC.  To identify the true gene transcription and reactivation events in HHV-8 infection, 
primary cells susceptible to HHV-8 should be used.  Only then can the observations from TPA 
induced BCBL-1 and Dox induced TREx-BCBL1-RTA cell lines be validated.  
1.1.3 Monocyte/macrophage infection with HHV-8 
Macrophages in several body compartments naturally express DC-SIGN (91, 117), as well as 
integrins including α3β1 (7), which presumably renders them susceptible to HHV-8 infection.  
An early report showed that MDM from normal donors that are stimulated in vitro with 
allogeneic PBMC can be infected by HHV-8, but this rarely results in complete, lytic replication 
(23).  In addition, treatment of blood monocytes from KS patients with proinflammatory 
cytokines in vitro results in HHV-8 persistence (166).    
MDM become susceptible to HHV-8 infection in vitro after activation with IL-13, which 
results in enhanced DC-SIGN expression (192).  IL-13 is an anti-inflammatory, T helper (Th) 2 
cytokine that promotes differentiation of B cells into antibody-secreting plasma cells.  
Importantly, non-IL-13 activated MDM express α3β1 integrin yet are not infected by HHV-8 in 
vitro, supporting the requirement of multiple receptors for efficient infection of APC by HHV-8.  
Indeed, when DC-SIGN is blocked in IL-13-activated MDM or the monocytic cell line THP-1, 
HHV-8 can still bind using heparan sulfate but virus entry is reduced (119).  HHV-8 establishes 
productive infection in THP-1 cells with an ordered expression of latency gene ORF73 and lytic 
gene ORF50.  In fact, the HHV-8 genome was reported to persist for 30 days in these cells (119).  
Such limited expression of lytic genes together with the persistence of latency genes is believed 
to be unique for HHV-8 (124).  
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Of interest is that ORF K14 of HHV-8 encodes a surface glycoprotein vOX2 that is 
homologous to cellular OX2 (46), which inhibits macrophage function (78).  The vOX2 
glycoprotein could be central to HHV-8 immunopathogenesis in that it stimulates production of 
inflammatory cytokines IL-1β, IL-6, monocyte chemoattractant protein 1 (MCP-1), and TNF-α 
in primary monocytes, MDM and MDDC (46).  Furthermore, expression of vOX2 on B cells 
stimulates monocytes to produce inflammatory cytokines.   MDM transfected with vOX2 
produce inflammatory cytokines and have enhanced phagocytic activity, while inhibiting the 
immunomodulatory effects of interferon gamma (IFN-γ) and down-regulating major 
histocompatibility complex (MHC) class I and class II expression on macrophages (206).  It was 
recently reported that vOX2-transfected APC co-cultured with T cells results in suppressed IFN-
γ  production and mobilization of the cytolytic granule marker CD107a through inhibition of 
extracellular signal-regulated kinase (ERK) 1/2 phosphorylation (165). 
1.1.4 HHV-8 infection of DC 
Evidence of infection of human DC in vivo with HHV-8 has been limited (181, 196).  However, 
there is no a priori reason why human DC should not take up HHV-8 and support at least 
abortive infection in vivo.  When MDDC are infected in vitro with HHV-8, viral lytic proteins 
are produced with little viral DNA production (192), similar to abortive HHV-8 infection of 
vascular endothelial cells (4, 175, 189, 195, 241).  Although HHV-8 infection does not 
significantly alter MDDC viability, it decreases MDDC function, i.e., lowers their capacity to 
activate antigen-specific CD8+ T cell responses.  Moreover, HHV-8 infected MDDC have 
impaired antigen uptake, with a significant decrease in endocytic capacity and DC-SIGN 
expression within 24 hours after infection.  DC-SIGN internalization in MDDC is associated 
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with lytic HHV-8 gene expression (192).  In addition to MDDC, HHV-8 in vitro infection of IL-
13-treated MDM results in a loss of DC-SIGN surface expression, suggesting that HHV-8 
binding to DC-SIGN triggers internalization.  Hence, alteration of DC-SIGN expression could be 
a strategy used by HHV-8 to escape immune defenses and lead it to a non-robust immune 
response (244). 
The skin and mucosa contain two major types of DC, Langerhans cells (LC) which reside 
in the epidermis in close contact with keratinocytes, and interstitial-dermal DC (iDDC) resident 
in the dermis and mucosal layers.  LC and iDDC process cutaneous antigens and migrate to 
draining lymph nodes to present antigens to T and B cells.  Because of the strategic position of 
LC and iDDC and their ability to capture pathogens, these cells could represent potential targets 
for HHV-8 infection.  Furthermore, due to the expression of the C-type lectins, i.e., langerin 
(CD207) and DC-SIGN, on LC and iDDC, respectively, it is tempting to speculate that HHV-8 
could utilize the same entry mechanisms as seen in MDDC (192).  LC and iDDC can be 
generated from pluripotent cord blood CD34+ cells (34) that could prove to be valuable tools to 
study HHV-8 infection and subsequent antigen process and presentation to T cells (50). 
Plasmacytoid DC (pDC) are a lymphoid-lineage subset of APC that produce 
extraordinary amounts of the antiviral protein IFN-α in response to virus infection (145).  DC-
SIGN is not expressed by pDC, yet HHV-8 can infect human pDCs, upregulate expression of the 
activation molecule CD83 and T cell co-receptor CD86, and induce production of IFN-α (249).  
Induction of IFN-α by HHV-8 occurs through activation of Toll-like receptor 9 (TLR9) signaling 
in pDC.  
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1.1.5 HHV-8 infection and TLRs 
Several types of TLR expressed on different APC are emerging as important factors in the innate 
and adaptive immune response to HHV-8.  Notably, triggering of C-type lectins, including DC-
SIGN, in combination with TLR triggering on DC induces signaling and cytokine responses, 
which in turn regulate T cell polarization that is central to host immune control of infections 
(238).  In addition, TLR have also been implicated in reactivation of HHV-8.  TLR 7/8 could 
control reactivation of HHV-8 from latency in B cells, as demonstrated by agonists specific for 
TLR7/8 reactivating latent HHV-8 and inducing viral lytic gene transcription and replication in 
latently infected PEL cell lines of B cell origin (92).  This has important implications for host 
control of HHV-8 infection, as signaling through the TLR1/2/6 complex, TLR7, TLR9 and 
TLR10 affects multiple stages of B cell activation, proliferation, cytokine secretion, terminal 
differentiation and antibody secretion in response to T cell-dependent antigens (14). 
1.2 CYTOKINES AND CHEMOKINES IN HHV-8 INFECTION                                                                                              
Cytokines and chemokines produced by inflammatory APC, as well as T cells, play a crucial role 
in HHV-8 replication and development of KS.  Inflammatory changes occur early in KS, prior to 
the detection of the cancer (162).  Proinflammatory processes drive early-stage KS to develop 
into mature, spindle cell lesions (197).  Thus, KS tumors are comprised of spindle shaped cells of 
endothelial origin (194) in an environment rich in inflammatory cell infiltrates, including B cells, 
macrophages, monocytes and CD8+ T cells (166).  The infiltrating cells produce large amounts 
of Th1 polarizing, proinflammatory cytokines (e.g., IFN-γ, IL-1β, TNF-α and IL-6), chemokines 
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(e.g., IL-8), and growth factors (e.g., vascular endothelial growth factor [VEGF]), which can 
induce the KS-like phenotype observed in activated endothelial cells (70, 75, 166).  IFN-γ is the 
earliest and most abundant inflammatory cytokine observed in KS (75) and can be detected in 
KS lesions before evidence of HHV-8 DNA (166).  IL-6 is also found at very high levels in both 
KS lesions and in circulation of patients with MCD (6).  In MCD, IL-6 induces B cell 
proliferation and causes inflammatory clinical symptoms (210).  Observations from a transgenic 
mouse model demonstrate that mice expressing viral IL-6 but lacking mammalian IL-6 do not 
experience phenotypic changes (e.g., lymphoadenopathy, hypergammaglobulinemia, 
splenomagaly) associated with MCD (230).  IL-6, as well as oncostatin M and IL-10, are also 
detected at high levels in PEL cells.  Proliferation of PEL can be inhibited when receptors for the 
IL-6 pathway are blocked (61).  Thus, an as yet minimally detailed imbalance in the Th1-Th2 
milieu during HHV-8 infection appears to be closely linked to APC in driving the outgrowth of 
KS endothelial cells as well as PEL and MCD B cells. 
Other cytokines and chemokines produced by APC, particularly IL-8 and MCP-1, are 
elevated in serum of KS patients and have been implicated in many cancers (160, 228).  When 
bound to its CCR2 receptor on endothelial cells, MCP-1 results in chemotaxis and has been 
shown to mediate angiogenesis in vitro (83, 160).  KS tumors are highly vascularized with 
abnormal angiogenesis, leading to enhanced blood flow to the tumor by expanding pre-existing 
blood vessels (162).  IL-1β, TNF-α, IL-8 and IL-6 can also enhance tumor cell growth and 
vascularization (68, 69, 75) by inducing the expression of two angiogenic mediators, i.e., VEGF 
and fibroblastic growth factor (FGF) (49, 51, 68, 166).  In addition to angiogenesis, 
inflammatory cells and cytokines can contribute to viral reactivation and replication.  IFN-γ was 
shown to induce ORF59 expression in BCBL-1 (22) and reactivate latent HHV-8 in BC-3 PEL 
 13 
cells by activation of Pim-family kinases (44).  Mercader et al. showed oncostatin M, IFN-γ, and 
hepatocyte growth factor (HGF)/ scatter factor (SF) induced lytic cycle activation of BCBL-1 
resulting in virion production (161).  This principle has been demonstrated in HHV-8 infected 
PBMC, where inflammatory cytokines could maintain or increase viral load up to 10-fold higher 
when the infected cells were cultured in the presence of inflammatory cytokines (166). 
In addition to cellular cytokines and chemokines, HHV-8 encodes several proteins 
involved in inflammation and angiogenesis that contribute to the inflammatory environment 
observed in KS.  Cytokine and chemokine mimics encoded by HHV-8 have been the focus of 
numerous studies and reviews (86, 133, 162, 176, 205, 216).  Thus, vIL-6 has 24% homology to 
human IL-6 and can induce expression of VEGF and MCP-1 (177).  These in turn trigger 
angiogenic pathways.  Elevated levels of vIL-6, as well as levels of human IL-6 and HHV-8 viral 
load, have been associated with a recently described syndrome of severe systemic inflammatory 
symptoms (237).  The viral G-protein coupled receptor (vGPCR) is an early lytic phase gene 
homologous to the IL-8 receptor, CXCR-2 (10, 176).  vGPCR constitutively signals and results 
in enhanced production of IL-1β, IL-8, MCP-1, IL-6 and VEGF that can have both autocrine and 
paracrine effects (87, 212).  K1 and K15 are signal transducing proteins that induce VEGF, IL-6 
and IL-8 (45).  LANA and the viral FLICE [FADD-like interferon converting enzyme]  
inhibitory protein (vFLIP) have been linked to enhanced cytokine production via activation of 
the mitogen activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signaling pathways, respectively (243).  Viral interferon regulatory 
factor 3 (vIRF3) expression inhibits MHC class II expression as well as IFN-γ production (208).  
Finally, the viral macrophage inflammatory proteins (MIPs) (viral chemokine ligand 1 [vCCL1], 
vCCL2, vCCL3) share homology to MIP-1α and CCL5 and can induce monocyte chemotaxis 
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and signal transduction (10, 174, 176).  Given the plethora of such data derived from highly 
manipulated molecular and cell line models, the challenge is to link these unique HHV-8 factors 
directly to HHV-8 infection and development of cancers in natural targets of the virus. 
In epidemic or AIDS-related KS, the immune dysregulation and induction of 
inflammatory cytokines acts to further enhance KS tumor growth.  When BCBL-1 cells that are 
latently infected with HHV-8 are cultured with HIV-1-infected CD4+ T cells, soluble factors 
secreted by the T cells cause the virus to enter lytic reactivation (161).  Inflammatory cytokines 
induced by both HIV-1-infected and HHV-8-infected cells promote expression of receptors for 
HIV-1 Tat, which acts as a progression factor in KS development (12, 67) and increases viral 
load  (97).  Indeed, serum and cell samples taken from KS lesions of HIV-1 infected individuals 
co-infected with HHV-8 show markedly increased levels of inflammatory cytokines, growth 
factors and angiogenic mediators (69, 186).  Furthermore, treatment of KS patients with IFN-γ, 
IL-2 and TNF causes KS progression (166). 
HHV-8 has a broad cellular tropism in vivo including B cells, endothelial cells, 
monocytes, keratinocytes and epithelial cells that could result in production of inflammatory 
mediators (38).  In monocytes, production of interferon gamma-induced protein (IP)-10, IFN-β1, 
MCP-1 and IRF-1 occurs in conjunction with an upregulation of TLR3 expression (248).  Our 
laboratory has previously demonstrated that in vitro HHV-8 infection of MDDC, which do not 
support lytic virus replication, secrete IL-6, TNF-α, IP-10, MIP-1α and MIP-1β (102).  While IL-
12p40 expression increases post-infection, bioactive IL-12p70 is not detected in HHV-8 infected 
MDDC.  This suggests a virus-related inhibition of constitutive production of IL-12p35, or a 
defect in the complexing of these subunits into IL-12p70.  Furthermore, the results support an 
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intentional skewing of cytokine production in HHV-8-infected MDDC towards induction of a 
Th2 response that could enhance development of KS. 
It is possible that upon exposure of B cells to HHV-8, the virus binds to and activates cell 
surface receptors resulting in cytokine and chemokine production that is enhanced by HHV-8 
entry and subsequent lytic replication.  The cytokine and chemokine profiles in HHV-8-infected 
B cells are similar to the cytokine dysregulation observed in EBV-associated disease (88, 89, 
122, 125).  Elevated levels of IL-1β, TNF-α, IL-6, IL-8 and IL-10 are detected in the serum of 
patients with EBV-associated diseases, while a less favorable outcome correlates with increases 
of IL-6 and IL-10 in Hodgkins lymphoma (72).  Common strategies between EBV and HHV-8, 
such as NF-κB signaling pathway alterations (56, 99) and the expression of virokines (216), 
imply that an imbalance of immune mediators is associated with the oncogenesis of these 
gammaherpesviruses. 
1.3 APC-T CELL INTERACTIONS IN HHV-8 INFECTION 
Little is known regarding HHV-8-specific T cell-APC interactions and their role in controlling 
viral infection and disease.  A key challenge is to adapt in vitro models using cell lines and 
HHV-8 constructs to systems that allow deciphering of the basic steps of natural HHV-8 
infection, and antigen processing and presentation, in various types of APC.  The interactions of 
APC with T cells that underlie the generation of anti-HHV-8 T cell immunity begin with DC of 
myeloid origin that take up viral antigen at local sites of infection, then travel to the draining 
lymphatics and induce antiviral T cell responses (236).  There are specialized subsets of DC that 
populate different tissue sites and have distinct virologic interactions and immunologic functions.  
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Myeloid-derived LC and dermal DC populate the epidermis and dermis respectively, and are 
associated with KS lesions.  Interstitial or interdigitating tissue DC are similar in phenotype and 
function to dermal DC, and are linked to systemic KS lesions.  Other DC subsets such as 
CD141+ DC, which are the human surrogates of mouse CD8α DC subsets (11, 114), could be 
natural targets for HHV-8.  It is imperative to assess transcription of HHV-8 ORFs in natural 
targets of the virus, in comparison to well documented immunomodulatory properties of HHV-8 
expressed in cell lines and artificial constructs, such as persistently infected BCBL-1 and its 
variants (52).  
Interactions of HHV-8 with DC subsets could be critical at the site of virus replication, 
and be centrally involved in generating T cell responses to the virus.  Efficient activation of 
HHV-8 epitope-specific CD8+ T cells requires presentation by peptide-loaded, autologous, 
mature MDDC (244).  This is similar to optimal activation of anti-EBV cytotoxic T lymphocyte 
(CTL) by peptide-loaded DC (143, 193, 224-227, 250).  Other studies have revealed 
polyfunctional CD8+ and CD4+ T cell reactivity and new MHC class I epitopes for HIV-1 Gag 
and Nef using peptide-loaded DC (108).  Importantly, our laboratory has used this DC model to 
map epitopes of HHV-8 lytic and latency proteins with libraries of synthetic, 15mer peptides 
overlapping by 11 amino acids (aa) (135).  Nevertheless, it may be more practical to generate 
large numbers of CD40 ligand (CD40L)-activated, autologous B cells that favourably compare to 
DC as APC (211).  
To date, relatively few CD8+ and CD4+ T cell epitopes within only 15 of the over 80 
ORFs of HHV-8 have been identified, and most of these are restricted by human leukocyte 
antigen (HLA) A*0201 (202).  Information is therefore needed on the broad range of potential 
antigenic sites in the virus that are restricted by other MHC class I and II haplotypes.  Moreover, 
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no studies have yet established a hierarchy of naïve and memory CD8+ or CD4+ T cell responses 
to HHV-8 epitopes in control of HHV-8 infection.  There also are minimal data on whether 
alterations in anti-HHV-8 T cell responses are related to development of KS (93) and whether 
the lower incidence of KS in HIV-1 infected persons receiving ART is related to increases in 
anti-HHV-8 T cell responses (19, 27).  This information is important for development of 
prophylactic and therapeutic vaccines for HHV-8. 
HHV-8 infection alters the capacity of DC to be recognized by and activate CTL.  Both 
direct presentation using viral proteins endogenously produced in DC, and cross-presentation 
pathways using viral proteins from exogenous sources of virus are likely to be operative in 
HHV-8 infection.  In fact, EBV does not replicate in MDDC, which instead activate anti-EBV 
CD8+ T cells by an antigen cross-presentation pathway (103, 183, 226).  
It is possible that HHV-8 infected, apoptotic endothelial cells, macrophages and B cells 
are recognized as “distressed” cells at local sites of infection and engulfed by LC and iDDC 
(236).  These DC then migrate to local lymph nodes while processing the ingested viral proteins 
through alternative MHC class I pathways for presentation to CD8+ T cells.  Furthermore, 
several HHV-8 proteins, particularly those coded by ORFs K3 and K5, have intriguing properties 
of altering expression of MHC class I, T cell co-receptors and DC-SIGN.  Interestingly, 
cytokines released by PELs can interfere with the in vitro differentiation of immature MDDC 
from CD14+ monocytes (47). 
An intriguing recent discovery is that activated CD4+ T cells suppress HHV-8 lytic 
replication in tonsillar B cells (168).  The suppressive activity requires cell-cell contact.  
However, it is not a classic CTL response, as it can be mediated by T cells from HHV-8 
seronegative persons, is not MHC restricted and does not lyse the B cell targets.  This is 
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proposed to be a pathway by which HHV-8 is driven into latency in B cells.  These CD4+ T cells 
are reminiscent of CD8+ T cells that exhibit non-cytotoxic responses that suppress HIV-1 
infection (120).   
1.3.1 Altered HHV-8 antigen processing and presentation 
Presentation of HHV-8 proteins to both CD8+ (MHC class I restricted) and CD4+ (MHC class II 
restricted) T cells is impaired by HHV-8 infection.  Evidence suggests that anti-HHV-8 CD8+ T 
cell responses can be inhibited by K3 and K5 proteins that down-regulate MHC class I 
expression (53, 111).  Interestingly, K5 encoded modulator of immune recognition 2 (MIR2) 
down-regulates T cell co-stimulatory molecules intercellular adhesion molecule 1 (ICAM-1) and 
CD86 (54) and IFNγR1 (141), which could act to decrease T cell responses to HHV-8.  Ishido et 
al. showed that K5 dampens natural killer (NK) cell-mediated cytotoxicity by down-regulation 
of ICAM-1 and CD86 (110).  The NK activating receptor, NKG2D, responsible for detecting 
infected cells, is down-regulated by HHV-8 K5 (233) via the release of the tumor-associated 
prostaglandin E2 (PGE2) from KS cells (66).  This also results in inhibition of IL-15-mediated 
NK cell activation and survival, adding to the immune escape tactics employed by this virus 
(66).  Likewise, infection of primary fibroblasts results in limited NK cell activation and 
subsequent killing activity (158).  Brander et al. (29) reported a decrease in lysis by HIV-1 
peptide-specific CTL clones of cells infected with HHV-8.  Thus, it is apparent that K3 and K5 
potentially have multifactorial effects on immune control of HHV-8 infection.  Of note is that the 
intracellular viral load of HHV-8 in infected endothelial cells is directly related to their loss of 
expression of MHC class I and ICAM-1, in association with expression of MIR2 (1).  
Interestingly, EBV infection also decreases recognition of latently infected cells by down-
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regulation of MHC class I molecules, particularly in cells derived from Burkitt’s lymphoma 
(106). 
MHC class II recognition is dampened by HHV-8 infection.  Sabbah et al. reported that 
LCL, with an intact MHC class II processing pathway, could present LANA peptides to LANA-
specific CD4+ T cell clones, whereas PEL cells were not recognized in an IFN-γ enzyme-linked 
immunosorbent spot (ELISPOT) assay (204).  PEL express vIRF3, a known inhibitor of the 
MHC class II master regulator, CIITA (class II transactivator) (208).  When CIITA function was 
restored in PEL, CD4+ T cell clone recognition was also restored (204), supporting a role for 
HHV-8 in the reduction of MHC class II expression.  Interestingly, IFN-γ inducible expression 
of CIITA results in MHC class II expression on endothelial cells, and is impaired after HHV-8 
infection through induction of suppressor of cytokine signaling 3 (SOCS3) (32).  This results in 
inhibition of the early events in the IFN-γ signaling pathway.  Taken together, various HHV-8 
proteins appear to play a significant role in the disruption of antigen processing and presentation.  
However, further data are needed to understand the extent of viral protein function in 
immunopathogenesis of HHV-8 infection in APC. 
1.3.2 T cell responses to HHV-8 
Although immunity to HHV-8 is far less well defined than that to EBV, T cell immunity to 
HHV-8 likely plays a similar, critical role in viral control.  First, there is an increase in CD4+ and 
CD8+ expanded T cells in patients with classic KS that share a T cell receptor (TCR)-β variable 
subunit bias (82), a phenomenon observed in response to chronic viral infections (235, 255).  
Second, CD8+ T cell immunity to HHV-8 proteins is present in HHV-8 seropositive, healthy 
individuals.  CD8+ T cells specific for five HHV-8 lytic cycle proteins are present in blood in the 
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first few months of primary HHV-8 infection of normal adults (245).  This primary CTL and 
IFN-γ response to HHV-8 peaks within two years of infection, and wanes thereafter to low but 
detectable levels.  Furthermore, KS does not commonly occur in individuals with a high CD4+ T 
cell counts (223).  
To date, however, there is little direct evidence for a role of T cell immunity in HHV-8 
infection and control of KS (105).  Lower CD8+ T cell responses have been found in persons 
with KS compared to asymptomatic persons (93, 128).  However, very modest increases in CD8+ 
T cell responses to HHV-8 immunodominant peptides are found in persons on ART (27, 251).  
While progressive increases in HHV-8 viral load precede development of disease in HIV-1-
infected persons (33, 130), evidence is lacking for a direct association between control of HHV-8 
load and HHV-8 specific T cell immunity (93).  Nevertheless, an increased incidence of KS in 
organ transplant recipients and HIV-1-infected persons (57) suggests a role for T cell immunity 
in prevention of KS, similar to T cell immunity in EBV-related cancers (90).  Reduction of 
immunosuppressive regimens can result in spontaneous resolution of KS in organ transplant 
recipients (76).  Similarly, the incidence of KS has declined after suppression of HIV-1 by ART 
(188), where T cell numbers and function are partially restored (15, 136, 199).  There are also 
shorter incubation periods for development of KS after HHV-8 infection in HIV-1-infected men 
compared to men infected with HHV-8 prior to HIV-1 infection (85, 112).  Primary infection 
with HHV-8 in immunosuppressed persons has a more severe outcome than reactivated HHV-8 
infection.  Finally, HHV-8 expresses many proteins that have immunomodulatory functions that 
could down-regulate T cell immunity (9).    
The emerging biology of KS and HHV-8 infection presents intriguing factors that 
interrelate HHV-8 specific T cell immunity to control of the cancer.  HHV-8 is found as a latent 
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infection in most of the spindle cells in the KS lesion (26, 65, 77, 167).  Since replication of 
herpesviruses in susceptible cells results in cell death, latency must be established either very 
soon after infection or possibly following an abortive (non-productive) infection.  A small 
percentage of endothelial and KS spindle cells express a complete replication library of HHV-8 
proteins early in the disease, whereas the majority of the transformed cells ultimately express 
only HHV-8 latency proteins.  Circulating B cells and monocytes can be positive for HHV-8 
DNA (6, 24), and HHV-8-infected macrophages are present in KS tissues (24).  Th1 cytokines 
have been implicated in reactivation and persistence of HHV-8 in B cells and monocytes from 
KS patients (217).  T cell infiltrates are common in KS tissues (24, 75).  CD8+ T cells in KS 
tissues produce IFN-γ and express HLA DR (75, 217), suggesting that tumor-infiltrating 
lymphocytes are responding to HHV-8 antigens. 
Comprehensive longitudinal studies are needed to accurately assess the role of anti-HHV-
8 T cell immunity in the development of KS.  T cell responses to HHV-8 could be directed at 
different lytic and latency proteins at different stages of infection and disease (90, 105).  By 
comparison, the immediate early regulatory protein BMLF1 and other early and late lytic cycle 
proteins of EBV are targets for CTL during primary and latent infection (25, 106, 221).  During 
mononucleosis, a primary symptomatic infection of EBV, both lytic and latency EBV-specific T 
cells are present, but responses to lytic epitopes tend to be stronger (149).  In healthy EBV 
seropositive individuals, CD8+ T cell responses are also found to be greater for lytic epitopes, 
with up to 3% of cells specific for a single lytic epitope and up to 0.5% for a single latency 
epitope (105).  Anti-EBV CTL responses shift during latent infection to EBV nuclear antigens 
EBNA3 and LMP2, while still retaining specificity for some lytic cycle proteins (104).  The 
hierarchy of CTL responses to immunodominant epitopes of EBV is related to a lower 
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expression of latency proteins in infected cells (185).  Although HHV-8 does not have genes 
homologous to EBNA and LMP, HHV-8 LANA, kaposin (T0.7 or ORF K12) and K1 are 
putative latency and transforming proteins that are targets for CTL (28, 135, 182).   
Host selection of CD8+ T cell epitopes within HHV-8 proteins could be based in part on 
the relative expression and presentation of viral proteins by the MHC class I endogenous 
pathway, comparable to EBV (138).  However, evidence from the anti-EBV CTL field indicates 
that CTL reactivity to this gammaherpesvirus varies as to the HLA haplotype, with different 
MHC class I haplotypes exhibiting different CTL reactivity to the same EBV proteins (106).  
Perhaps HHV-8 has mechanisms similar to the glycine-alanine repeat domain in EBNA1 (183) 
that inhibits proteosome processing of viral proteins through the MHC class I pathway (106, 
137), thereby inhibiting generation of EBNA1-specific T cells.  In fact, LANA-1 can inhibit 
protein processing in cis (126, 257).  Bioinformatic analysis of HHV-8 sequences supports that 
latency proteins are likely to be poorer targets for CTL than immediate early or lytic proteins 
(240).  However, it is not yet clear if the in cis function of LANA-1 is directly involved in down-
regulation of CTL lysis of HHV-8 infected cells, including how it compares to other putative, in 
trans inhibitors of CTL function such as K3 and K5.  Moreover, the EBNA1-CTL inhibition 
concept has undergone major revision.  First, the GAr domains of EBNA1 can inhibit mRNA 
translation, which may be more critical to lack of CTL recognition than inhibition of 
proteosomal processing (256).  Second, EBNA1 infected cells express EBNA1 peptides that can 
be recognized by CTL when assessed in more sensitive assays (134).  This indicates that the 
effects of LANA-1 on pathways related to CTL function that use chimeric constructs, indicator 
cell lines, etc., need to be characterized in a natural context using CTL and natural targets that 
are specific for LANA-1.  
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Similar to EBV, CD8+ T cell responses to HHV-8 tend to be directed more toward lytic 
antigens (200).  While there are much fewer CD8+ T cell epitopes known for HHV-8 than EBV, 
the majority of these epitopes are within the early and late-lytic proteins (201, 202).  With regard 
to polyfunctionality, one study found that for both EBV and HHV-8, T cells specific for latency 
antigens were more polyfunctional than those specific for lytic antigens (20).  The phenotype of 
these cells was also found to be different, with a greater proportion of effector memory T cells 
specific for latency antigens than lytic antigens for both EBV and HHV-8.  In both EBV and 
HHV-8-associated malignancies, latency proteins are predominantly expressed, so it is thought 
that responses to latency proteins could be important in controlling these diseases (105, 231).  
Evidence suggests that there are higher levels of CTL specific for EBV and cytomegalovirus 
(CMV) than HHV-8 in the blood of seropositive individuals (93, 244).  Higher T cell responses 
to EBV and CMV antigens could be related to their greater viral load in persistently infected 
persons, with more turnover of viral antigen from latent, persistent reservoirs that maintains a 
greater level of memory CTL precursors.  
Antigen-specific CD8+ T cells occupy a lineage of naïve and memory compartments that 
are involved in the expansion, effector and contraction phases of CD8+ memory T cells (96).  
Central memory and effector memory T cells are contrasted based on expression of surface 
molecules related to migration and differentiation.  Patients with MCD have more 
CD45RA¯CCR7¯CD27¯CD8+IFN-γ+ cells (a late memory T cell phenotype) and fewer 
CCR7¯CD27+CD45RA¯ cells (early and intermediate T cell phenotype) than normal, HHV-8 
seropositive controls.  This phenotypic shift is not found for EBV-specific CD8+ T cells.  
Interestingly, HHV-8 viral loads are negatively correlated with early and intermediate effector 
memory cells.  The more differentiated T cell phenotype is associated with disease, rather than a 
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loss of HHV-8 specific CD8+ T cells or polyfunctional activity, as the HHV-8 specific T cells are 
similar in function (secretion of IFN-γ, TNF-α, MIP1-β, and/or CD107a) in infected patients and 
healthy controls (94).   
In healthy, HHV-8 seropositive individuals controlling infection, both monofunctional 
and polyfunctional CD8+ T cells are present that are specific for HHV-8 proteins (135).  This 
could have important implications in the immunopathogenesis of HHV-8 and for HHV-8-related 
disease development.  In fact, patients who control KS have more polyfunctional CD8+ T cells 
producing IFN-γ and TNF-α, while patients with progressive KS have weaker and less 
polyfunctional HHV-8-specific CD8+ T cells (17).  IFN-γ-producing CTL specific for some 
HHV-8 lytic and latency proteins also express CD107 and TNF-α (20).  This is similar to 
polyfunctional CTL that produce multiple cytokines, such as IFN-γ, IL-2 and MIP-1β, that are 
associated with enhanced control of HIV-1 infection (16, 153, 222).  Also, CTL specific for EBV 
lytic and latency proteins differ in phenotype, including expression of programmed death-1 (PD-
1) (106).  PD-1 expression could act as a negative regulator of HHV-8 specific CD8+ T cells 
during disease progression. 
While both monofunctional and polyfunctional antiviral CD8+ T cells are present in 
healthy HHV-8 seropositive individuals, a week-long DC-enhanced system was required to 
reveal these responses to HHV-8 proteins (244).  Overall, the immune response to HHV-8 is 
relatively non-robust compared to T cell reactivity to other herpesviruses such as EBV (20, 135).  
This suggests that the number and/or functional capacity of circulating anti-HHV-8 T cells is 
relatively low.  However, using direct, multimer staining, we have found that there is an average 
of 0.05-0.10% circulating, CD8+ T cells specific for single, immunodominant MHC class I 
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epitopes of HHV-8 in healthy, HHV-8 seropositive individuals (135).  It is possible that these 
HHV-8-specific T cells are functionally down-regulated by T regulatory cells (Treg).  
Treg are operative in peripheral tolerance and beneficial in preventing autoimmunity and 
tissue damage.  These cells function through mechanisms including IL-10 and transforming 
growth factor (TGF)-β inhibitory cytokine secretion, granzyme cytolytic activity, metabolic 
disruption through the adenosine and IL-2 pathways, and suppression of DC function using the 
inhibitory receptor CTLA-4 (242).  However, Treg can also inhibit immunity needed to resolve 
infections.  While little is currently known about Treg during HHV-8 infection and disease 
development, these cells have been found to be important during other viral infections, including 
EBV (139) and HIV-1 (151).  During primary EBV infection, patients with mononucleosis have 
less Treg than healthy seropositive individuals (253).  In patients with Hodgkins lymphoma, 
Treg accumulated at tumor sites, and those patients with higher Treg ratios had shorter disease-
free survival (154, 209).  Additionally, in these patients, several EBV epitopes stimulate Treg, 
and the increases in Treg numbers are associated with decreased EBV-specific CD8+ T cell IFN-
γ production (155).  In patients with nasopharyngeal carcinoma, large numbers of Treg are found 
both at tumor sites and in circulation (132, 140).  During HIV-1 infection, HIV-1 specific CD8+ 
T cell responses and cytolytic activity are repressed by Treg (121).  Additionally, an increased 
Treg frequency negatively alters CD8+ T cell polyfunctionality, which is restored with Treg 
depletion (152).  As Treg could also be important in HHV-8-related disease development, such 
as KS, studies are needed to determine their exact role.   
This chapter was published as: Professional Antigen Presenting Cells in Human 
Herpesvirus 8 Infection, E. Knowlton, L. Lepone, J. Li, G. Rappocciolo, F. Jenkins and C. 
Rinaldo. Frontiers in Immunology, 2013, 3 (427): 1-18. 
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1.4 HYPOTHESIS AND SPECIFIC AIMS 
HHV-8 is a gammaherpesvirus that causes KS, PEL and MCD.  The importance of determining 
effective prevention and treatment for HHV-8 infection is evident in that KS continues to be the 
most common cancer among HIV-1 and AIDS patients (48).  CD8+ T cell immunity likely plays 
a significant role during HHV-8 infection as these cells have been shown to be crucial in 
controlling infections caused by the other human gammaherpesvirus, i.e., EBV (105).  I 
hypothesized that monofunctional and polyfunctional CD8+ T cells specific for HHV-8 lytic and 
latency proteins are important in controlling HHV-8 infection.  Loss of this reactivity to 
immunodominant epitopes is due in part to the down-regulation of CD8+ T cell responses by 
Treg, contributing to the development of KS.  In support of this hypothesis, our laboratory has 
shown that CD8+ T cells produce IFN-γ in response to HHV-8 immunodominant epitopes in 
HHV-8 seropositive individuals (244).  Polyfunctional T cells, i.e., single cells producing two or 
more immune mediators, have been linked to control of HIV-1 (16) and could play a role in 
controlling HHV-8 infection.  Treg have been shown to modulate immune responses during 
other persistent viral infections (142), but it is currently unknown if they are important during 
HHV-8 infection.  Identifying the viral regions targeted by the immune system and mechanisms 
that interfere with T cell responses could be critical for the development of effective treatments 
and vaccines for HHV-8-associated cancers such as KS.  The specific aims of this project were: 
1.4.1 Specific aim I 
To define MHC class I epitopes that generate CD8+ T cell responses to HHV-8 proteins and 
investigate the presence of polyfunctional T cell responses.  T cells isolated from HHV-8 
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seropositive, HLA A*0201 donor PBMC were stimulated with autologous dendritic cells loaded 
with overlapping peptides derived from glycoprotein B (gB) and K8.1 lytic proteins, and LANA-
1 and K12 latency proteins.  To define novel immunodominant epitopes, T cell responses were 
evaluated using an IFN-γ ELISPOT.  To investigate polyfunctional responses, positive peptides 
were then assessed for IFN-γ, IL-2, TNF-α, MIP-1β and CD107a production by flow cytometry.  
To directly detect HHV-8-specific T cells in the blood, multimer complexes were used. 
1.4.2 Specific aim II 
To determine the magnitude and breadth of CD8+ T cell responses to HHV-8 proteins during the 
progression to KS.  Longitudinal studies were performed using Multicenter AIDS Cohort Study 
(MACS) participants, including HHV8+/HIV- individuals as well as HHV8+/HIV+ individuals 
that did and did not develop KS.  To compare CD8+ T cell responses before and after HHV-8 
seroconversion and the development of KS, multimer and phenotype staining were performed 
using known epitopes and epitopes defined in specific aim I. 
1.4.3 Specific aim III 
To investigate the role of Treg during the progression to KS.  Longitudinal studies were 
performed using MACS participants from specific aim II.  To compare CD8+ T cell responses 
before and after HHV-8 seroconversion and the development of KS, ELISPOT assays were 
performed using known epitopes and epitopes defined in specific aim 1.  Experiments were 
performed using PBMC and PBMC depleted of Treg. 
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2.0  DETECTION OF POLYFUNCTIONAL T CELL RESPONSES TO HHV-8 
HHV-8 is the etiological agent of KS, PEL and MCD.  It is postulated that CD8+ T cell responses 
play an important role in controlling HHV-8 infection and preventing development of disease.  
As this is not clear, however, we investigated monofunctional and polyfunctional CD8+ T cell 
responses to HHV-8 lytic proteins gB and K8.1, and latency proteins LANA-1 and K12.  Based 
on our previous findings that DC reveal MHC class I epitopes in gB, we used a DC-based system 
to identify two gB, two K8.1, five LANA-1 and one K12 novel epitopes.  These new HHV-8 
epitopes activated both monofunctional and polyfunctional CD8+ T cells that produced various 
combinations of IFN-γ, IL-2, TNF-α, MIP-1β and cytotoxic degranulation marker CD107a in 
normal, HHV-8 seropositive individuals.  We were also able to detect HHV-8-specific CD8+ T 
cells in the peripheral blood using HLA A*0201 pentamer complexes specific for one gB, one 
K8.1, two LANA-1 and one K12 epitopes.  These immunogenic regions of viral lytic and latency 
proteins could be important in T cell control of HHV-8 infection. 
The work in this chapter was published as: Monofunctional and Polyfunctional CD8 T 
Cell Responses to Human Herpesvirus 8 Lytic and Latency Proteins, L. Lepone, G. Rappocciolo, 
E. Knowlton, M. Jais, P. Piazza, F. Jenkins and C. Rinaldo. Clinical and Vaccine Immunology, 
2010, 17 (10): 1507-1516. 
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2.1 BACKGROUND 
HHV-8, also referred to as KSHV, is a gammaherpesvirus that causes KS, PEL and MCD.  The 
importance of developing effective prevention and treatment for HHV-8 infection is evident in 
that KS, a neoplasm of endothelial origin, continues to be the most common cancer among HIV-
1-infected patients (48).  It is also the leading cause of cancer in children in sub-Saharan Africa 
(31).  Although the incidence of KS in HIV-1-infected persons declined with the advent of ART 
(81), KS can occur in persons on ART with suppressed HIV-1 infection and high CD4+ T cell 
counts (159).   
 The immune responses responsible for controlling HHV-8 infection and preventing KS 
are not clear.  CD8+ T cell immunity likely plays a significant role in HHV-8 infection, as these 
cells have been shown to be crucial in controlling infection caused by the other human 
gammaherpesvirus, i.e., EBV (90, 105).  In support of this hypothesis, our laboratory (244-246) 
and others (20, 27, 28, 93, 128, 148, 163, 180, 182, 198, 200, 220, 223, 251, 254) have shown 
that CD8+ T cells produce IFN-γ in response to HHV-8 immunodominant epitopes presented by 
MHCI in HHV-8 seropositive individuals.  Little is known about whether T cells produce other 
immune mediators in response to HHV-8 infection.  Indeed, polyfunctional T cells, i.e., single 
cells producing two or more immune mediators, have been linked to control of HIV-1 and other 
persistent infections (16, 153, 184, 213), and could play a role in controlling HHV-8 infection.  
In one recent study, HHV-8 epitope-specific, polyfunctional T cells were detected in patients 
with MCD, but these did not differ in number from those in normal controls (94).  Another study 
found that patients with controlled KS had HHV-8-specific CD8+ T cells that secreted IFN-γ and 
TNF-α, while patients with progressive disease had weaker and less polyfunctional CD8+ T cells 
(17).   
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 HHV-8 epitope-specific, monofunctional and polyfunctional T cell immunity could be 
important in the development of HHV-8 vaccines that induce T cell responses that target these 
viral epitopes.  We therefore investigated CD8+ T cell responses to two HHV-8 lytic proteins, gB 
and K8.1, and two latency proteins, LANA-1 and K12.  Our laboratory has previously shown 
that optimal induction of T cell reactivity to the HHV-8 protein gB required one week of 
stimulation with peptide-loaded, autologous, mature, MDDC (244).  Using this enhanced DC-T 
cell stimulation system, we now have revealed several new epitopes for these four lytic and 
latency HHV-8 proteins in normal, HHV-8 seropositive individuals, which induce both 
monofunctional and polyfunctional CD8+ T cells.  These regions of HHV-8 could be critical in 
understanding HHV-8 immunopathogenesis and in vaccine development. 
2.2 METHODS 
2.2.1 Study subjects 
Healthy, HIV-1 negative subjects were selected based on their HHV-8 antibody status and MHCI 
genotype, and written informed consent was obtained.  Detection of HHV-8 serum antibodies 
specific for viral lytic antigens was done using an indirect immunofluorescence assay (244).  
High resolution, HLA molecular typing was conducted by the University of Pittsburgh Medical 
Center Tissue Typing Laboratory.  The donors were classified into HLA A*0201, HHV-8 
seropositive and HLA A*0201, HHV-8 seronegative groups. 
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2.2.2 Synthetic peptides 
For initial studies, libraries of 15mer peptides overlapping by 11aa derived from K12, gB and 
K8.1 protein sequences were synthesized (PEPscreen, Sigma).  For the larger protein LANA-1, a 
library of 15-20mer peptides overlapping by 11 aa was used.  Protein sequences were obtained 
from the National Center for Biotechnology Information database, with LANA-1 accession 
number AAD46501, K12 number AAD46499, gB number ABD28851 and K8.1 number 
ABD28902.  As LANA-1 contains a large repeat region, we used one set of representative 
peptides to span this region (peptide numbers 59-75).  For epitope mapping studies, putative 
optimal 9mer peptides were synthesized based on anchor residues for HLA A*0201 (190), as 
well as peptides one N- or C-terminus amino acid shorter and longer than optimal (107).  The 
following previously published 9mer, HLA A*0201-restricted, HHV-8 epitopes were also used: 
LANA-1238-246 WATESPIYV (93), LANA-11116-1124 QMARLAWEA (93), K1217-25 
LLNGWRWRL (28), gB492-500 LMWYELSKI (244) and K8.1209-217 LVLILYLCV (27). 
2.2.3 T cell stimulation 
CD14+ cells were isolated from donor PBMC using anti-CD14 mAb-coated magnetic beads 
(Miltenyi Biotec).  Immature DC were generated by culturing CD14+ cells (1x106) for 7 days in 
AIM-V medium (GIBCO) containing 1,000 U/mL each of recombinant IL-4 (R&D Systems) and 
recombinant granulocyte-monocyte colony-stimulating factor (GM-CSF) (Bayer Health Care) at 
37°C in a 5% CO2 atmosphere.  Fresh IL-4 and GM-CSF were added every 2 days.  On day 5, 
CD40L (1μg/mL, R&D) was added to induce maturation.  Mature DC were loaded with peptide 
(2μg/mL) for 2 hours (h) at 37°C.  Culture medium and peptide concentration were chosen based 
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on a comparison of assay conditions (see supplemental figures in Appendix B, Figure 16).  To 
assess T cell reactivity, we used DC as APC and autologous CD14− cells as responders (244).  
Antigen-loaded DC or DC without antigen (1x104 cells) were mixed with CD14− cells (1x105) 
and co-cultured for 7 days in AIM-V at 37°C, with 100 U/mL IL-2 (Chiron) added on day 2.  T 
cell stimulation was assessed in HHV-8 seronegative donors as controls. 
2.2.4 Single-cell IFN-γ production 
Following a 7 day co-culture of peptide-loaded mature DC stimulators and CD14− cell 
responders, our DC-enhanced, single-cell IFN-γ ELISPOT assay was performed based on our 
previously described method for assessing T cell reactivity (244).  Briefly, nitrocellulose-
bottomed, 96-well ELISPOT plates (Millipore) were pre-coated with an anti-IFN-γ mAb 
(10μg/mlL, Mabtech) overnight at 4°C then blocked for 2 h at 37°C with RPMI 1640 medium 
(GIBCO) supplemented with 10% heat-inactivated human AB+ serum (Gemini Bio-Products).  
Autologous PBMC (1x104) were loaded with peptide (2μg/mL) for 2 h at 37°C then combined 
with week-long T cell cultures described above to serve as APC.  These samples were added to 
ELISPOT plates, cultured overnight at 37°C, and developed as previously described (50).  Spots 
were counted using an ELISPOT reader (AID).  The results were expressed as virus-specific 
spot-forming cells per million cells by subtracting the number of spots in T cell cultures 
stimulated by DC without peptide from the number of spots induced by DC with peptide.  T cell 
responses were considered positive if the number of spots produced by cells stimulated with 
peptide was greater than the number of spots produced by cells not stimulated with peptide. 
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2.2.5 Generation of T cell lines 
HHV-8 epitope-specific T cell lines were generated to confirm the novel epitopes and their HLA 
A*0201 restriction.  Frozen PBMC were thawed, washed and resuspended in RPMI 1640 
medium with 10% heat-inactivated fetal calf serum (FCS) (Cellgro).  Cells were added to a 24-
well plate at 2x106 cells per well and kept at 37°C.  Peptides were added at 10μg/mL.  On day 3, 
IL-2 was added (100 U/mL), with fresh IL-2 added every 3 days for a total of 15 days.  On day 
15, a B cell line that only expresses one MHCI haplotype, HLA A*0201, was used as an APC; a 
B cell line that does not express HLA (null) was used as a control (214).  The B cells were 
loaded with peptide (2μg/mL) for 2 h at 37°C and then used as APC with the 15 day cultured 
cells in an IFN-γ ELISPOT assay performed as described above. 
2.2.6 MHCI binding assay 
HLA A*0201 binding experiments were performed by ProImmune with their class I REVEAL 
binding assay.  Briefly, the assay determines the binding of a peptide to an HLA molecule by its 
ability to stabilize the MHC-peptide complex.  Binding is scored relative to a positive control of 
a known T cell epitope with very strong binding properties.  A score is reported quantitatively as 
a percentage of the signal generated by the test peptide versus the positive control peptide. 
2.2.7 Pentamer staining 
Along with analysis of immune responses by IFN-γ ELISPOT, MHCI pentamers were also used 
to quantify epitope-specific CD8+ T cells.  Based on the results of the ProImmune class I 
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REVEAL binding assay described above, five high-affinity HLA-A*0201 binding peptides were 
used to generate MHC class I-peptide pentamer complexes (ProVE pentamers, ProImmune).  
Frozen PBMC (1-2x106 cells per well) were thawed, washed and then incubated for 10 minutes 
(min) with unlabeled pentamer (0.5μg per test).  The cells were washed and then stained for 20 
min in the dark with phycoerythrin (PE)-conjugated Pro5 Fluorotag (8μL per well, ProImmune), 
CD3- allophycocyanin-Cy7 (5μL per well, BD) and CD8-peridinin chlorophyll protein (PerCP)-
Cy5.5 (20μL per well, BD).  CD4-V450, CD19-V450 and CD14-V450 (all from BD) were also 
added at 5μL each per well for exclusion gating.  Cells were washed and fixed with BD 
stabilizing solution and analyzed on an LSR II flow cytometer (BD Immunocytometry Systems). 
2.2.8 ICS and polychromatic flow cytometry 
Intracellular staining (ICS) for various immune mediators was performed as described (16, 129), 
with minor modifications.  On day 7 of the DC-enhanced T cell cultures described above, cells 
were collected and plated (1-2x106 cells per well).  The peptide stimulus (10μg/mL), 
costimulatory CD28/49d mAb (1μg/mL, BD), monensin (5μg/mL, Sigma), brefeldin A (5μg/mL, 
Sigma), and anti-CD107a-fluorescein isothiocyanate (FITC) (20μL per well, BD) were added.  
Unstimulated cells were also included.  The cells were incubated for 6 h at 37°C, and then 
ethylenediaminetetraacetic acid (EDTA) (2mM) (GIBCO) was added.  The cells were washed 
and resuspended in 100μL phosphate-buffered saline (PBS) (GIBCO) per well containing 
1μL/well aqua viability dye (Invitrogen) for 30 min in the dark.  The cells were washed and 
resuspended in 1x fluorescence-activated cell sorting (FACS) lysis solution (BD) and kept at 4°C 
overnight.  Cells were washed and permeabilized using 1x Perm solution (BD), and then washed 
and stained for 45 min in the dark with the directly conjugated antibodies CD3- allophycocyanin 
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-Cy7, TNF-α-PE-Cy7, MIP-1β-PE, IL-2-allophycocyanin, IFN-γ-AF700, with 5μL each per 
well, and CD8-PerCP-Cy5.5 (all from BD) at 20μL per well.  CD4-V450, CD19-V450, and 
CD14-V450 (all from BD) were also added at 5μL each per well for exclusion gating.  Cells 
were washed and fixed with BD stabilizing solution and analyzed on an LSR II flow cytometer.  
Results were analyzed with Boolean gating to create the full array of possible cytokine 
combinations using BDFACS Diva (v6.0) software.  Polyfunctional bar and pie charts for each 
peptide were created using Simplified Presentation of Incredibly Complex Evaluations (SPICE) 
software (v4.2.3, provided by Mario Roederer, VRC/NIAID/NIH). 
2.2.9 Statistics 
We used analysis of variance (ANOVA) and the Student t test for comparisons between 
groups. 
2.3 RESULTS 
2.3.1 Novel T cell epitopes in HHV-8 lytic and latency proteins 
To define MHCI epitopes that generate CD8+ T cell responses to HHV-8 proteins, a DC-
enhanced IFN-γ ELISPOT assay was used.  This was based on our previous finding that this 
method was necessary to reveal an epitope in HHV-8 gB due to the non-robust nature of the 
immune response to HHV-8 in normal, HHV-8 seropositive persons (244).  We confirmed this 
finding with the donors used in the current study by comparing responses to previously published 
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epitopes in a standard, overnight and a DC-enhanced, 7 day ELISPOT assay (see supplemental 
figures in Appendix B, Figure 17).  Therefore, T cells were stimulated with autologous mature 
DC that were loaded with overlapping peptides derived from HHV-8 LANA-1, K12, gB and 
K8.1, and single cell IFN-γ production was measured by an ELISPOT assay.   
 The IFN-γ ELISPOT results for four HLA A*0201, HHV-8 seropositive donors (A29, 
A34, A52 and A57) to peptides from each viral protein are displayed in Figure 1.  For the larger 
proteins LANA-1 and gB, peptides containing possible epitopes, termed “hotspots” (Figure 1, 
circled), were defined as peptides that generated a positive response above the background of 
mock-stimulated cells in all donors tested, and with at least one donor responding in the highest 
category (red boxes).  For the smaller proteins K12 and K8.1, we considered hotspots as those 
peptides that the majority of donors responded to above background, and at least one donor 
responded in the highest category.  For LANA-1, out of 106 peptides tested, we found eight 
hotspots (Figure 1A).  For K12, out of 13 peptides tested, we found one hotspot (Figure 1B).  For 
gB, out of 235 peptides tested, we found nine hotspots, including one containing our previously 
described epitope (244) (Figure 1C).  For K8.1, out of 60 peptides tested, we found three 
hotspots including two containing previously described epitopes (27, 251) (Figure 1D).  Two 
HLA A*0201, HHV-8 seronegative donors did not respond above background to any of these 
hotspots from the four viral proteins.  Thus, these hotspots represented regions of the four HHV-
8 proteins that displayed positive reactivity associated with HHV-8 seropositivity. 
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Figure 1. ELISPOT responses to four HHV-8 lytic and latency proteins 
PBMC from HLA A*0201, HHV-8 seropositive, healthy donors were stimulated with autologous, mature DC that 
were loaded with overlapping 15-20mer peptides derived from each of the HHV-8 proteins LANA-1, K12, gB and 
K8.1.  IFN-γ production was measured by a DC-enhanced ELISPOT assay, and the number of spots produced by 
cells without peptide was subtracted from spots produced by cells with peptide to give net values of spots.  The 
donors (three to four donors used for each protein) are listed in each row, while the representative peptide numbers 
are listed in each column.  The colors for the boxes represent the net IFN-γ spots per million cells as:  <1,  1-
199,  200-399,  400-599 and  ≥600 spots.  Hotspots are circled for LANA-1 (A), K12 (B), gB (C), and K8.1 
(D). 
 38 
We next mapped minimal epitope sequences for 10 of these hotspot peptides.  To 
determine the minimal, optimal epitope, we used peptide families consisting of the putative 
optimal 9mer based on anchor resides for HLA A*0201, along with peptides one N- or C- 
terminus aa truncation (8mers) and extension (10mers).  Initially, we adapted the conventional 
method to define optimal T cell epitopes, i.e., T cell response to different concentrations of N- 
and C-terminal extensions and truncations of peptide in a standard overnight ELISPOT assay, to 
our 7 day, extended assay.  However, stimulating PBMC for 7 days with DC loaded with five 
different, 10-fold concentrations of these peptide families did not differentiate a dominant 
peptide response (see supplemental figures in Appendix B, Figure 18).  Therefore, we tested the 
peptide families for the optimal epitopes by stimulating the cells for 7 days with a single 
concentration of peptide followed by a conventional, 16 hour ELISPOT assay using the same 
peptide.  We assessed five peptide families from LANA-1, one from K12, two from gB and two 
from K8.1.  One of the hotspots we identified (K8.1 peptide 38, Figure 1D) contained a 
published 15mer epitope (251).  Therefore, we included this peptide family to determine the 
minimal epitope sequence.  Two of the hotspots (gB peptide 139, Figure 1C, and K8.1 peptide 
56, Figure 1D) contained previously published 9mer epitopes (27, 244) that we included as 
controls.  As shown in Figure 2, the DC-enhanced assay revealed positive IFN-γ responses for 
the known HHV-8 epitopes as well as for the peptide families of each protein.  We defined the 
optimal epitope as the peptide from each family that generated the highest IFN-γ production 
above background (i.e., mock-stimulated cell cultures).  By these approaches we were able to 
define five novel, minimal epitope sequences for LANA-1, one for K12, two for gB and two for 
K8.1 (Table 1). 
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Figure 2. ELISPOT responses to peptide families derived from hotspots 
PBMC from HLA A*0201, HHV-8 seropositive, healthy donors were stimulated for one week with autologous 
mature DC that were loaded with peptide.  IFN-γ production was measured as in Figure 1.  Mean + SE spot forming 
cells from 10 experiments using three donors in response to DC loaded with peptide families are shown for LANA-1 
(A) and K12, gB and K8.1 (B), and known gB492-500 and K8.1209-217 epitopes (B).   
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Table 1. Novel HHV-8 HLA A*0201 epitopes identified in LANA-1, K12, gB and K8.1 
Protein Peptide 
numbera 
Amino acid 
position 
Sequence 
LANA-1 17 140-148 PESSQRPPL 
LANA-1 33/34 281-289 AMLVLLAEI 
LANA-1 48 417-425 DGGDGNKTL 
LANA-1 63 688-697 QQDEQQQQDE 
LANA-1 83 920-928 PVVSTHEQI 
K12 7/8 23-32 WRLGAIPPLV 
gB 44 159-168 SSMKVNVNGV 
gB 207 736-745 MLMIIIVIAI 
K8.1 21 73-81 RLAAGSPSS 
K8.1 38 135-143 ALISAFSGS 
a Representative peptide numbers from Figure 1. 
 
 
 
2.3.2 MHCI restriction and binding of novel HHV-8 epitopes 
To verify that the novel epitopes were HLA A*0201-restricted, we generated epitope-specific T 
cell lines and used B cells that only express HLA A*0201 (A2 cells) or do not express any HLA 
(null cells) as APC in a standard ELISPOT assay.  Positive IFN-γ responses using A2 cells as 
APC were evident to our five novel LANA-1 epitopes, one novel K12 epitope, two novel gB 
epitopes and two novel K8.1 epitopes (Figure 3, black bars).  IFN-γ responses were also detected 
when using A2 cells as APC for our previously determined HLA A*0201-restricted gB epitope 
(244) (Figure 3, black bars).  For all peptides tested, responses were lower when the null B cells 
were used as APC (Figure 3, grey bars).  Taken together, these results support that our novel 
epitopes from the four HHV-8 proteins are HLA A*0201-restricted. 
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Figure 3. T cell line ELISPOT responses using HLA A2 cells as APC 
PBMC from HLA A*0201, HHV-8 seropositive healthy donors were stimulated with peptide-loaded DC, with IL-2 
added every 3 days.  On day 15, B cell lines expressing only HLA A*0201 (A2 cells) or no HLA molecules (null 
cells) were used as APC.  IFN-γ production was measured by ELISPOT as in Figure 1.  Responses to novel epitopes 
from LANA-1, K12, gB and K8.1, and a known epitope from gB (gB492-500) are shown for one representative donor 
out of two donors used. 
 
 
 
 
 Having demonstrated that these peptides are presented in the context of the HLA 
A*0201, we then tested them in an MHCI binding assay to confirm their specificity.  To this end, 
ProImmune performed their class I REVEAL binding assay on our novel minimal epitopes as 
well as several known epitopes from the four HHV-8 proteins used in our study.  The binding 
rates are reported as percent relative to the binding of a known, strong HLA A*0201 T cell 
epitope.  The peptides that showed high binding (i.e., above the intermediate control of a known, 
weaker HLA A*0201 T cell epitope) were three known epitopes (gB492-500, K1217-25, LANA-
11116-1124) as well as two of our novel epitopes (LANA-1281-289, K8.1135-143), which supports that 
all of these peptides are HLA A*0201-restricted, T cell epitopes (Figure 4).  The remaining 
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novel epitopes were classified as weak binders, i.e., below the intermediate control (Figure 4).  
However, these binding scores are relative measures and general guidelines.  Thus, peptides 
classified as weak binders are not necessarily poor T cell epitopes.  Indeed, two known epitopes 
(LANA-1238-246, K8.1209-217) were classified as weak binders in this assay (Figure 4).  Overall, we 
conclude that our peptides are novel HLA A*0201 epitopes. 
 
 
 
 
 
Figure 4. ProImmune class I REVEAL binding assay results 
The binding score for each peptide is shown as relative to a positive control of a known T cell epitope with very 
strong HLA A*0201 binding properties.  Binding scores are shown for our ten novel epitopes (black bars), five 
known epitopes (grey bars) and the positive and intermediate control peptides (striped bars). 
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2.3.3 Direct identification of CD8+ T cells specific for HHV-8 epitopes 
Based on the highest scores of the peptide-MHC class I binding results, we synthesized five 
HLA A*0201 pentamers for two novel epitopes, LANA281-289 and K8.1135-143, and three known 
epitopes, gB492-500, K1217-25 and LANA-11116-1124.  As displayed in Figure 5, the mean (±standard 
error [SE]) percent of epitope-specific CD8+ T cells in eight healthy, HLA A*0201, HHV-8 
seropositive individuals was 0.048% (±0.010) for LANA281-289, 0.050% (±0.012) for LANA-
11116-1124, 0.053% (±0.018) for K1217-25, 0.050% (±0.009) for gB492-500 and 0.096% (±0.020) for 
K8.1135-143.  The mean levels of pentamer-positive CD8+ T cells was 0.020% (±0.003) in three 
healthy, HLA A*0201, HHV-8 seronegative individuals (Figure 5).  Overall, the level of 
pentamer-positive, CD8+ T cells in the seropositive donors was significantly greater than that in 
the seronegative donors (p-value<0.05). 
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Figure 5. HLA A*0201 pentamer staining in peripheral blood samples 
PBMC from HLA A*0201, HHV-8 seropositive donors were stained with fluorotag alone or MHC class I-peptide 
pentamer complexes specific for LANA-1281-289, LANA-11116-1124, K1217-25, gB492-500 and K8.1135-143.  Results are 
shown for one representative HHV-8 seropositive and one representative seronegative donor (A) and for all eight 
HHV-8 seropositive donors tested (B, with averages indicated by the black bars). 
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2.3.4 Monofunctional and polyfunctional T cell responses to HHV-8 
There are many cytokines in addition to IFN-γ, as well as chemokines and cytotoxic molecules, 
that are important in antiviral T cell responses.  Moreover, polyfunctional T cells, which are 
defined as a single cell producing two or more such immune mediators, are an important immune 
correlate of protection against HIV-1 disease progression (16).  As it is currently not clear 
whether monofunctional and polyfunctional CD8+ T cells play a role in controlling HHV-8 
infection, we used a panel of markers for immune mediators to examine polyfunctional CD8+ T 
cell responses.  This panel included the cytokines IFN-γ, TNF-α and IL-2, the chemokine MIP-
1β and the degranulation mobilization marker CD107a.  We used a modified procedure with DC-
enhanced T cell cultures for the ICS assay developed in our laboratory (109) to improve 
detection of production of these immune mediators (representative analysis in Figure 6).  
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Figure 6. Representative gating strategy to define the expression of immune mediators 
Cells were stimulated with media or the known epitope gB492-500 and stained for T cell surface markers and the 
expression of CD107a, MIP-1β, TNF-α, IFN-γ, IL-2.  Top, the progressive gating strategy used to define the CD8+ 
population; middle and bottom, the results of the five functional responses of the CD8+ T cells. 
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As shown in Figure 7, positive responses for a variety of immune mediators were 
detected to several known epitopes and to our novel minimal epitopes.  The data are shown as 
bars representing the frequency of the listed mediator combination, with each color representing 
a different viral peptide.  Each pie chart represents total responses to the listed peptide, with each 
color representing the number of cytokines produced.  The ICS results revealed that in healthy 
HHV-8 seropositive individuals controlling infection, HHV-8 latency and lytic protein epitopes 
induced both monofunctional and polyfunctional CD8+ T cell responses (Figure 7).  Although all 
of the peptides displayed a trend of more monofunctional responses than polyfunctional 
responses, the differences were not significant.  Taking into consideration all of the HHV-8 
epitopes tested, all five immune mediators were produced by monofunctional T cells, with a 
predominance of IFN-γ, IL-2 and CD107a (Figure 7).  Polyfunctional T cells producing two 
immune mediators were notable for the combinations of IFN-γ and IL-2 and for MIP-1β and IL-
2.  Predominant patterns of polyfuctional responses for three immune mediators included IFN-γ, 
TNF-α and CD107a, and MIP-1β, IL-2 and CD107a.  Polyfunctional T cells producing four 
immune mediators included IFN-γ, TNF-α, MIP-1β and CD107a, and IFN-γ, TNF-α, IL-2 and 
CD107a.  
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Figure 7. Polyfunctional CD8 T cell responses to known and novel HHV-8 epitopes 
PBMC from HLA A*0201, HHV-8 seropositive healthy donors were stimulated for one week with autologous 
mature DC loaded with known HHV-8 epitopes (A) or novel epitopes from LANA-1 (B), K12, gB or K8.1 (C).  
Responses were measured by polychromatic flow cytometry and net responses were averaged for three donors 
(mean + SE).  Diagrams were generated using SPICE. 
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Different HHV-8 epitopes induced different patterns of both monofunctional and 
polyfunctional responses.  For example, the known epitope from gB (gB492-500) induced notable 
monofunctional responses consisting of IL-2 or CD107a, and polyfunctional responses MIP-1β 
and IL-2, and IFN-γ, TNF-α and CD107a (Figure 7A).  The known epitope K8.1 (K8.1209-217) 
displayed notable monofunctional responses consisting of IFN-γ or TNF-α, and polyfunctional 
responses in the combinations of CD107a and TNF-α, MIP-1β, TNF-α and IFN-γ, and MIP-1β, 
TNF-α, IFN-γ and CD107a (Figure 7A).   
The traditional method to map epitopes is through an IFN-γ ELISPOT assay.  However, 
while analysis using one marker allows for the determination of response magnitude, the 
inclusion of several markers provides insight regarding the quality of the response.  Therefore, 
along with our novel and known HHV-8 epitopes, we also investigated polyfunctional responses 
to one peptide family from each of the four HHV-8 proteins included in our study (Figure 8).  
While trends were evident, no single peptide had a significantly higher magnitude of responses 
or more polyfunctional responses than the other peptides within the peptide families examined. 
Taken together, these results show that the CD8+ T cell epitopes from the four HHV-8 proteins 
presented by DC induced a variety of both monofunctional and polyfunctional T cell responses 
in HHV-8 seropositive healthy donors.  The specificity of this T cell response is less evident in 
polyfunctional T cell determinations. 
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Figure 8. Polyfunctional CD8 T cell responses to HHV-8 peptide families 
PBMC from HLA A*0201, HHV-8 seropositive healthy donors were stimulated for one week with autologous 
mature DC loaded with peptide.  Peptide families are shown for LANA-1 17 (A), K12 7 (B), gB 44 (C) and K8.1 21 
(D).  Responses were measured by polychromatic flow cytometry and net responses were averaged for three donors 
(mean + SE).  Diagrams were generated using SPICE. 
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2.4 DISCUSSION 
It is postulated that CD8+ T cell responses play a significant role in controlling HHV-8 infection 
and preventing development of KS (17, 93).   A central issue in understanding the CD8+ T cell 
immunity in HHV-8 infection is the identification of MHCI epitopes for the more than 80 ORFs 
of the virus.  This has been difficult to do mainly because of relatively non-robust CD8+ T cell 
responses to the virus (144).  In this study, we employed a DC-based enhancement of CD8+ T 
cell responses to four HHV-8 lytic and latency proteins modified from our previous approach 
(244) to provide a greater insight to immunopathogenesis of the virus.  Using this DC-enhanced, 
IFN-γ ELISPOT assay, we have revealed five LANA-1, one K12, two gB and two K8.1, novel, 
HLA A*0201-restricted, CD8+ T cell epitopes.  We were also able to detect epitope-specific 
CD8+ T cells directly in the peripheral blood using HLA A*0201 pentamer complexes specific 
for one gB, one K8.1, two LANA-1 and one K12 epitope.  These results were expanded and 
confirmed by using a DC-enhanced ICS assay with polychromatic flow cytometry to detect 
multiple immune mediators.  By this approach, we revealed that HHV-8 seropositive healthy 
donors controlling infection have circulating, monofunctional and polyfunctional CD8+ T cells 
specific for an array of HHV-8 lytic and latency protein epitopes.   
 The novel epitopes in our study did not all correspond to published motifs for the 
preferred HLA A*0201 anchor residues at positions 2 and 9.  Such lack of correspondence to 
MHCI allele-specific, peptide motifs has been recognized for T cell epitopes of other viruses.  
For example, the immunodominant, HLA A*0201-restricted, influenza A virus M158-66 epitope 
GILGFVFTL does not have the preferred HLA A*0201 anchor residue L or M in position 2 
(215).  Moreover, over half of the HLA A*0201-restricted epitopes for vaccinia virus do not fit 
the optimal peptide binding motif (215).  Aside from binding to MHCI molecules, there are other 
 52 
important factors that determine the T cell response to a peptide, such as the presence CD8+ T 
cell precursors, interactions with T cell receptors and peptide transporters, and generation of 
peptides by different protease cleavage pathways (18, 163).  Furthermore, our epitopes were 
determined by two different functional assays (ELISPOT and ICS), and represent CD8+ T cell 
positive reactivity in HLA A*0201, HHV-8 seropositive individuals. 
 Given the large number of ORFs in HHV-8, we focused on ORFs that code for lytic and 
latency proteins that are considered important in HHV-8 pathogenesis and oncogenesis. We 
selected two latency cycle proteins, LANA-1 and K12, and two lytic cycle proteins, gB and 
K8.1.  The lytic protein gB is a virion glycoprotein that binds cell surface heparan sulfate and 
induces signaling pathways, and the lytic protein K8.1 is a highly immunogenic (antibody 
inducing) virion glycoprotein that also binds cell surface heparan sulfate (244, 251).  During 
latency, LANA-1 is a cell cycle regulatory protein important in anti-apoptotic functions and 
episome maintenance.  The K12 (kaposin) latency protein has roles in B cell signaling, apoptosis 
and cell transformation induction (93, 163).  While we do acknowledge that a limitation of our 
study is the small sample size, we found T cell reactivity to peptides of these lytic and latency 
proteins, indicating that immunity to each could be important in control of HHV-8 infection.  In 
our next study, we then applied a battery of our newly identified and previously documented 
epitopes to assess T cell immunity to HHV-8 infection and progression to KS in the Multicenter 
AIDS Cohort Study.   
Remarkably, given the need to use DC to reveal this T cell function, direct staining of 
PBMC with HLA A*0201 pentamer complexes for two lytic and three latency protein epitopes 
identified antigen-specific CD8+ T cells circulating in peripheral blood.  HHV-8 specific CD8+ T 
cells have been previously detected in the blood of HHV-8 seropositive patients, including 
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transplant recipients, and those with AIDS-related and classical KS (128).  However, to our 
knowledge, this is the first direct evidence of HHV-8-specific CD8+ T cells in blood of healthy 
HHV-8 seropositive individuals.  In our next study, we determined the memory phenotype of 
these circulating T cells, and investigated if there is a functional down-regulation of these cells.   
 Previous studies have shown that the central repeat region of LANA-1 inhibits 
proteasomal degradation and slows protein synthesis in order to inhibit cellular surveillance for 
CD8+ T cell epitopes (126).  This model predicts that host T cell reactivity to LANA-1 would be 
minimal.  However, we detected CD8+ T cell reactivity to several regions of LANA-1 in these 
normal, healthy HHV-8 seropositive subjects.  Others have shown anti-LANA-1 CD8+ T cell 
responses in patients with KS (93).  Similarly, CD8+ T cell recognition has been found for EBV-
encoded nuclear antigen 1 (134, 232), which previously had been proposed to escape CD8+ T 
cell recognition through cis-inhibition of synthesis or blockade of proteasomal degradation by its 
glycine-alanine repeat domain.  Thus, it appears that CD8+ T cells can mount functional 
responses to certain regions of LANA-1 regardless of cis effects on its production.  
 Polyfunctional CD8+ T cells, i.e., cells producing more than one immune mediator, are 
associated with superior control of persistent viral infections such as HIV-1 (16, 153).  A recent 
investigation found similar patterns of polyfunctional T cell responses in patients with MCD and 
normal controls (94).  Other investigators have reported that patients with non-progressive KS 
have stronger and more frequent polyfunctional CD8+ T cell responses than those with 
progressive KS (17).  It is not known, however, whether polyfunctional CD8+ T cell are involved 
in control of latent HHV-8 infection in healthy, HHV-8 seropositive persons.  In the present 
study, we established that polyfunctional T cells specific for known and novel epitopes are 
present in the PBMC of such individuals.  We found that in these healthy, non-
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immunosuppressed subjects controlling HHV-8 infection, there was a trend of more 
monofunctional CD8+ T cell responses compared to polyfunctional responses for all of the 
epitopes.  Overall, our data suggest that the tight control of HHV-8 infection in normal 
individuals may not require a predominance of circulating, virus-specific, polyfunctional CD8+ T 
cell reactivity.  Furthermore, we found that different epitopes induced different patterns of 
monofunctional and polyfunctional responses.  Similar results were found for T cell responses to 
influenza virus, where CD8+ T cells specific for some but not all viral proteins produced a wide 
range of cytokines (127).  This could be explained by differences in T cell avidity for the 
peptide-MHC complex.  
 Traditionally, the standard in monitoring CD8+ T cell responses has been measuring 
single cell IFN-γ production in response to antigenic stimuli by an overnight ELISPOT assay.  
While analysis using one marker allows for the determination of response magnitude, the 
inclusion of several markers provides insight regarding response quality.  Therefore, we 
examined ICS responses to families of putative optimal epitopes consisting of peptides with N- 
and C-terminal extensions and truncations from each viral protein to further delineate the 
minimal epitope sequences.  We found that there were different patterns of T cell reactivity 
revealed by ICS as compared to the ELISPOT assay.  This stresses the need to move beyond 
IFN-γ ELISPOT assays in defining T cell immunity to viral infections (16, 229).  The data also 
suggest that CD8+ T cells can mount diverse, functional reactivity to 8-10mer variants of an 
MHCI 9mer epitope when presented by DC.  This is supported by a recent finding in our 
laboratory that DC are able to generate efficient, monofunctional and polyfunctional T cell 
responses against 8-10mer N- and C-terminal variants  of HIV-1 Gag and Nef epitopes (108).  
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This enhancement of T cell responses by DC to peptide variations could also explain the broad 
spectrum of ELISPOT responses evident in our HHV-8 epitope mapping study.   
 In conclusion, we have revealed several novel HLA A*0201 minimal epitopes in both 
HHV-8 lytic and latency proteins.  We have also shown the presence of antigen-specific CD8+ T 
cells in the peripheral blood specific for two lytic and three latency protein epitopes.  We have 
demonstrated that epitopes within these HHV-8 lytic and latency proteins induced both single 
and multiple immune mediators in CD8+ T cells from healthy, HHV-8 seropositive individuals.  
The likely involvement of CD8+ T cells in the immune response to HHV-8 infection has 
implications for the prevention and treatment of HHV-8-associated cancers.  These targeted 
regions of the virus that induce immune responses by CD8+ T cells could be critical in HHV-8 
immunopathogenesis and the progression to KS. 
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3.0  T CELL RESPONSES DURING THE PROGRESSION TO KS 
CD8+ T cells are considered important in controlling HHV-8 infection, the causative agent of KS 
and some B cell lymphomas. However, these T cell responses are relatively non-robust, 
suggesting that they are under tight regulatory control.  We have conducted a longitudinal study 
of the effect of Treg on CD8+ memory T cell reactivity to HHV-8 lytic and latency proteins after 
HHV-8 infection, with and without HIV-1 coinfection, and subsequent development of KS in the 
MACS.  Direct staining of PBMC with MHCI multimers showed a relatively high frequency of 
circulating, HHV-8 lytic and latency antigen-specific CD8+ T cells, but negative or very low 
IFN-γ production by ELISPOT assay.  Removal of Treg significantly enhanced IFN-γ production 
of CD8+ T cells against HHV-8 lytic and latency antigens throughout the course of HHV-8 
infection, with or without HIV-1 coinfection.  Anti-HHV-8 and anti-HIV-1 T cell activity were 
lower during the years prior to development of KS compared to subjects who did not develop 
KS.  This was related to a higher number of circulating Treg but less enhancement of the 
antiviral CD8+ T cell response after removal of Treg prior to KS.   These data show for the first 
time that Treg suppress CD8+ T cell responses to HHV-8 lytic and latency antigens, effectively 
masking more robust, underlying anti-HHV-8 T cell responses. During HIV-1 coinfection, 
decreases in these antiviral T cell responses, even after removal of the Treg effect, are related to 
subsequent development of KS.  The involvement of CD8+ T cells and Treg in control of HHV-8 
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infection has important implications for understanding the immunopathogenesis of HHV-8 
infection and development of vaccines to prevent KS. 
3.1 BACKGROUND 
HHV-8 is the etiologic agent of KS, a neoplasm of endothelial origin, which is the most common 
cancer associated with HIV-1 infection and AIDS (48).  While the incidence of KS in HIV-1 
infected individuals has decreased with the use of effective ART (81), KS still occurs in those on 
ART with suppressed HIV-1 infection (159). The success of ART in treating HIV-1 associated 
KS has been countered by the occasional occurrence of immune reconstitution inflammatory 
syndrome (73).  This is a severe, temporary enhancement of KS lesions due to an increase in 
inflammation and immunologic recovery after ART.  The development of effective treatments of 
the infection and cancer with drugs, or the prevention of both with a vaccine, requires an intimate 
understanding of the pathogenesis and immune control of HHV-8 infection. 
 Although immunity to HHV-8 is far less well defined than that to the other human 
gammaherpesvirus, EBV, CD8+ T cells likely play a similar, critical role in viral control (105).  
In support of this hypothesis, our laboratory has previously found that CD8+ T cells specific for 
several HHV-8 lytic proteins are present in the blood in the first few months of primary 
infection, which peaks within two years of infection then decreases to low but detectable levels 
(245).  We have also shown that HHV-8 monofunctional and polyfunctional CD8+ T cells are 
present in healthy, HHV-8 seropositive adults controlling infection (135).  To date, there are 
minimal data on whether alterations in anti-HHV-8 T cell responses are directly related to KS 
development (93, 128), and if the lower incidence of KS in HIV-1 infected individuals on ART 
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is related to increases in anti-HHV-8 T cell responses (19, 27).  Therefore, comprehensive 
longitudinal studies are needed to accurately assess the role of anti-HHV-8 T cell immunity in 
the development of KS. 
 While CD8+ T cell responses to both HHV-8 lytic and latency proteins are evident in 
HHV-8 seropositive individuals, the immune response to this virus is relatively non-robust 
compared to T cell reactivity to other human herpesviruses, such as EBV (20, 135).  This 
suggests that the number and/or functional capacity of circulating anti-HHV-8 T cells is 
relatively low.  However, using direct, multimer staining, we have found that a reasonably high 
level of these circulating T cells specific for HHV-8 proteins is present in seropositive 
individuals (135).  Therefore, we hypothesized that anti-HHV-8-specific CD8+ T cells are 
functionally down-regulated by Treg.  In support of this hypothesis, these regulatory cells have 
been found to play a role during other viral infections, including EBV (139) and HIV-1 (151).  
However, it is currently unknown if these cells are important during HHV-8 infection and 
disease development. 
 To provide insight into the importance of CD8+ T cell responses and the effect of Treg on 
the development of KS, we conducted a non-concurrent, prospective, multiparameter study of T 
cell immunity in HHV-8 infected participants in the MACS who did or did not develop KS.  We 
found that anti-HHV-8 T cell reactivity was under control of Treg in healthy HHV-8 seropositive 
persons. During HHV-8/HIV-1 coinfection, decreases in these antiviral T cell responses, even 
after removal of the Treg effect, were related to development of KS.  The involvement of CD8+ 
T cells and Treg in control of HHV-8 infection has important implications for our understanding 
of HHV-8 immunopathogenesis and development of vaccines to prevent KS. 
 59 
3.2 METHODS 
3.2.1 Study participants and samples 
Participants were chosen from the Pittsburgh site of the MACS, a national longitudinal study of 
the natural history of HIV-1 infection in men who have sex with men that began in 1984 (118).  
Approximately every 6 months, participants visit the clinics to provide epidemiologic 
information and biologic samples, which are obtained with informed consent and following 
protocols approved by institutional review boards.  Clinical information is recorded in the MACS 
database, and biologic samples are cryopreserved and stored in local and national repositories.   
 Participants were chosen based on HIV-1 and HHV-8 infection status, as well as clinical 
diagnosis of KS (112).  Additionally, participants were chosen based on their MHC class I type, 
as known HLA A*0201-restricted epitopes were used in the study assays.  An indirect 
immunofluorescence assay was used to detect HHV-8 serum antibodies (112).  HHV-8 viral load 
was determined by PCR as previously described (178, 187, 219).  HIV-1 viral load was 
determined using Roche Ultrasensitive RNA PCR assay (Hoffman-LaRoche).  T cell counts 
were determined using flow cytometry (207).  The participants were classified into HIV-1-
positive/HHV-8-positive/KS-negative or KS-positive groups, with 10 participants in the KS-
negative group and five participants in the KS-positive group.  Four HIV-1-negative/HHV-8-
positive individuals were included to investigate the natural history of HHV-8 infection without 
the presence of HIV-1 co-infection.  Three HIV-1-negative/HHV-8-negative were included as 
controls.  PBMC and serum samples were chosen within a year of KS diagnosis and the 
corresponding time point for those that did not develop KS.  Four additional time points were 
chosen of 8-12, 6-8, 4-6 and 2-4 years prior to KS diagnosis.  Average T cell counts and HIV-1 
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and HHV-8 viral loads at the chosen visits are shown below.  All participants were Caucasian 
men, with an average age of 35 (range 22-64) at study entry. 
3.2.2 Dextramer staining 
To determine the frequency of epitope-specific CD8+ T cells, PE-conjugated HLA A*0201 
dextramers were used (Immudex).  Dextramers were specific for five HHV-8 epitopes (LANA-
1281-289  (135), LANA-11116-1124  (93), K1217-25  (28), gB492-500  (244) and K8.1135-143 (135)).  As 
controls, detraxmers specific for an immunodominant HIV-1 (SL9, p1777-85) epitope (146), an 
immunodominant CMV (N9V, pp65495-503) epitope  (252), and an HLA A*0201 negative 
dextramer were also included.  Staining was performed according to the manufacturer's protocol.  
Briefly, frozen PBMC (1-2 million cells per dextramer well) were thawed, washed and 
resuspended  in 100µL PBS (GIBCO) per well containing 1µL per well aqua viability dye 
(Invitrogen) for 30 min at room temperature in the dark.  The cells were washed with PBS 
containing 5% FCS (Cellgro) and incubated with 10µL of dextramer for 10 min at room 
temperature in the dark.  Cells were then stained for 30 min in the dark at 4ºC with CD8-PerCP-
Cy5.5 (BD, 20µL per well), CD3-allophycocyanin-Cy7 (BD, 5µL per well), CD45RA-PE-Cy7 
(BD, 5µL per well), CD57-FITC (BD, 20µL per well), CCR7-allophycocyanin (R&D, 10µL per 
well) and CD27-PC5 (Beckman Coulter, 10µL per well).  CD4-V450, CD19-V450, and CD14-
V450 (all from BD, 5µL each per well) were also added for exclusion gating.  Cells were washed 
twice and fixed with PBS containing 1% paraformaldehyde (PFA).  Samples were analyzed with 
an LSR II flow cytometer (BD Immunocytometry Systems), and results were analyzed using 
BDFACS Diva (version 6.0) software. 
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3.2.3 Treg staining 
To determine the frequency of Treg, frozen PBMC (1-2 million cells per well) were thawed, 
washed and resuspended  in 100µL PBS per well containing 1µL per well aqua viability dye for 
30 min at room temperature in the dark.  The cells were washed and then stained for 30 min in 
the dark at room temperature with CD4-V450, CD8-PerCP-Cy5.5, CD3-allophycocyanin-Cy7 
and CD25-allophycocyanin (BD, 5µL per well).  Samples were then washed twice and fixed 
with PBS containing 1% PFA.  Samples were analyzed with an LSR II flow cytometer, and 
results were analyzed using BDFACS Diva software. 
3.2.4 Treg depletion and cell stimulation 
To investigate the effect of Treg on CD8+ T cell function, frozen PBMC samples were thawed 
and depleted of Treg using a Treg CD4+CD25+ isolation kit (Miltenyi Biotec).  Briefly, this two-
step column-based kit uses magnetic beads to first negatively select CD4+ cells by labeling all 
the non-CD4 cells.  Treg are then positively selected from the CD4+ fraction using anti-CD25 
mAb-coated magnetic beads.  Treg-depleted samples consisted of the non-CD4 fraction from the 
first step plus the CD4+CD25- non-Treg fraction from the second step.  To assess HHV-8 T cell 
reactivity, PBMC and PBMC that were depleted of Treg were stimulated with four different 
peptide pools.  An HHV-8 latent antigen pool consisted of nine HLA A*0201 eptiopes (LANA-
1140-148 (135) , LANA-1238-246  (93), LANA-1281-289, LANA-1417-425  (135), LANA-1688-697 (135), 
LANA-1920-928  (135), LANA-11116-1124, K1217-25, K1223-32  (135), all from Sigma).  An HHV-8 
lytic antigen pool consisted of six HLA A*0201 epitopes (gB159-168  (135), gB492-500, gB736-745 
(135) , K8.173-81  (135), K8.1135-143, K8.1209-217  (27), all from Sigma).  As controls, a CEF peptide 
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pool was used (32 MHCI T cell epitopes from CMV, EBV and FLU (55), National Institutes of 
Health [NIH] AIDS Reagent Program).  A pool consisting of 12 HLA A*0201 epitopes from 
HIV-1 was also used (p1777–85, p2p7p1p670–79, p2419-27, PR76–84, RT33–41, RT179–187, RT309–317, Vpr 
59–67, gp160311–320, gp160813–822, Nef 136–145, Nef 180–189, (146), all from Sigma).  Cells stimulated 
with RPMI 1640 medium (GIBCO) supplemented with 10% FCS were used as a negative 
control. 
3.2.5 Single-cell IFN-γ production 
To assess T cell reactivity, a standard overnight IFN-γ ELISPOT assay was performed.  Briefly, 
nitrocellulose-bottomed, 96-well ELISPOT plates (Millipore) were precoated with an anti-IFN-γ 
mAb (10 µg/ml, Mabtech) overnight at 4°C and then blocked for 2 h at 37°C with RPMI 1640 
medium supplemented with 10% heat-inactivated human AB+ serum (Gemini Bio-Products).  
PBMC (100,000 cells per well) or PBMC depleted of Treg (100,000 cells per well) were 
stimulated with peptide pools (10µg/mL) or medium and added to ELISPOT plates, cultured 
overnight at 37°C, and developed as previously described (50).  Spots were counted using an 
ELISPOT reader (AID). The results were expressed as net numbers of virus-specific spot-
forming cells per million cells by subtracting the number of spots in cultures stimulated with 
medium from the number of spots induced by peptide. 
3.2.6 Serum biomarker assay 
Frozen serum samples were thawed and tested for the presence of several biomarkers relating to 
Treg function and KS development using an electrochemiluminescence Meso Scale Discovery 
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(MSD) multi-array assay.  Samples were tested using ultra-sensitive kits for human IFN-γ, IL-10, 
IL-2, IL-6, IL-8, TNF-α, IL-1β, IL-12, IL-13, IL-4, IL-5, MIP-1β, MIP-1α and TGF-β, and a 
human serum kit for VEGF (MSD).  All assays were performed according to the manufacturer's 
protocol for serum samples.  Both samples and standards were performed in duplicate.   Plates 
were read on a SECTOR Imager 2400 electrochemilumuinescence machine (MSD) and data 
were analyzed using the Discovery Workbench (version 3, MSD). 
3.2.7 Statistics 
We used ANOVA and the Student t test for comparisons between groups.  Differences were 
considered significant with p-value<0.05. 
3.3 RESULTS 
3.3.1 Levels of HHV-8 specific CD8+ T cells over many years prior to KS 
We have previously shown that both monofunctional and polyfunctional CD8+ T cells specific 
for HHV-8 lytic and latency proteins are present in healthy, HHV-8 seropositive adults 
controlling infection (135).  In order to investigate the role these cells play in controlling HHV-8 
infection to prevent disease development, we applied multimer staining to PBMC from MACS 
subjects obtained many years prior to KS development. Subjects who were co-infected with 
HIV-1 and HHV-8 and developed KS had significantly lower CD4+ T cell counts than HHV-
8/HIV-1 co-infected non-KS controls 4-6 years prior to KS (p=0.023) that persisted through KS 
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diagnosis (p<0.001 at both 2-4 and 0-1) (group averages in Figure 9B, individual donors in 
Appendix C).  Levels of CD3+ T cells (p=0.014) (Figure 9A) and CD8+ T cells (p=0.013) (Figure 
9C) were also significantly different between groups within a year of KS.  This immunologic 
deficit was not associated with differences in plasma viral load for HIV-1 until one year prior to 
KS (p=0.002) (Figure 9D). Although not significant, plasma viral load for HHV-8 was also 
higher in the KS cases within a year of diagnosis of KS (Figure 9E). 
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Figure 9. T cell counts and viral loads in MACS subjects 
Three HIV-/HHV8-, four HIV-/HHV8+, 10 HIV+/HHV8+/KS- and five HIV+/HHV8+/KS+ subjects were selected 
from the Pittsburgh MACS.  Five visits were chosen, with one visit within a year of KS development in the cases 
and the corresponding visit in the controls, a second visit 2-4, a third visit 4-6, a fourth visit 6-8 and a fifth visit 8-12 
years prior to KS development. Mean (±SE) CD3+ (A), CD4+ (B) and CD8+ (C) T cell counts at each visit were 
determined by flow cytometry.  Mean (±SE) HIV-1 (D) and HHV-8 (E) plasma viral load at each visit were 
determined by PCR. (*= p<0.05 by ANOVA) 
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 To directly investigate the frequency of HHV-8-specific CD8+ T cells in the blood during 
the progression to KS, HLA A*0201 multimers were used for three latency epitopes (two 
LANA-1, one K12) and two lytic epitopes (one gB, one K8.1).  In our previous studies, we used 
pentamers to define epitope-specific CD8+ T cells (135).  However, in our current studies, we 
used dextramers, as these have more MHC and fluorochrome molecules than pentamers.  This 
produces higher affinity staining, which results in brighter epitope-specific staining and lower 
non-specific background staining.  We confirmed this through a direction comparison of a CMV-
specific pentamer and dextramer (see supplemental figures in Appendix B, Figure 19).   
Using dextramer staining, higher levels of HHV-8-specific CD8+ T cells were found in 
HHV-8 seropositive subjects than seronegative subjects (Figure 10).  For all groups, relatively 
constant levels of HHV-8, CMV and HIV-1 epitope-specific CD8+ T cells were found over time 
(Figure 10).  The average frequency of HHV-8 latentcy and lytic epitope-specific CD8+ T cells 
ranged from 0.1-0.3% in HIV-/HHV8+ subjects (Figure 10A), 0.05-0.2% in HIV+/HHV8+/KS- 
subjects (Figure 10B) and 0.01-0.2% in HIV+/HHV8+/KS+ subjects (Figure 10C).  Additionally, 
cells specific for HHV-8 lytic epitopes tended to be higher than those specific for latency 
epitopes in all groups (Figure 10A-C).  When comparing averages among groups, there was a 
significant difference of HHV-8 epitope-specific T cells as early as 6-8 years prior to KS 
development (p<0.001), which continued up to a year within KS (p=0.002 at 4-6 years, p=0.001 
at 2-4 years and p=0.001 at 0-1 year) (Figure 10D).  Levels were highest in the HIV-/HHV8+ 
group, lower in the HIV+/HHV8+/KS- group and lowest in those who developed KS (Figure 
10D).   
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Figure 10. HHV-8 epitope-specific CD8 T cells over many years prior to KS 
MACS subjects were used as described in Figure 9.  Staining assays were performed using dextramers specific for 
five HHV-8 epitopes, one HIV-1 epitope and one CMV epitope.  A negative HLA A*0201 dextramer was used as a 
control to set the staining gates.  Mean (±SE) levels of epitope-specific cells are shown for HIV-/HHV8+ (A, n=4), 
HIV+/HHV8+/KS- (B, n=10) and HIV+/HHV8+/KS+ (C, n=5) subjects over time.  Mean levels for HIV-/HHV8- 
subjects (n=3) are shown by the dotted line.  Overall means compared by group are shown for HHV-8 (D), CMV (E) 
and HIV-1 (F) epitopes. (*= p<0.05 by ANOVA) 
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In all groups, frequencies of HIV-1-specific T cells were higher than HHV-8-specific 
cells, and frequencies were highest for CMV-specific cells (Figure 10).  The average frequency 
of CMV epitope-specific CD8+ T cells ranged from 0.4-0.9% in HIV-/HHV8+ subjects (Figure 
10A), 0.9-1.2% in HIV+/HHV8+/KS- subjects (Figure 10B) and 0.6-2.1% in 
HIV+/HHV8+/KS+ subjects (Figure 10C).  The average frequency of HIV-1 epitope-specific 
CD8+ T cells ranged from 0.2-0.5% in HIV+/HHV8+/KS- subjects (Figure 10B) and 0.3-0.6% in 
HIV+/HHV8+/KS+ subjects (Figure 10C).  Differences among groups were less evident for 
CMV-specific cells (Figure 10E) and HIV-1-specific cells (Figure 10F) than for HHV-8-specific 
cells.   
Overall, these data show that HHV-8-specific CD8+ T cells are lower many years prior to 
the development of KS, and continue to decrease until development of KS.  T cell reactivity to 
HHV-8 lytic epitopes was higher than to latency epitopes throughout the time course of the 
study. 
3.3.2 Phenotypes of CD8+ T cells for virus-specific and nonspecific cells 
As the state of differentiation of CD8+ T cells is important for immune control of infections, we 
investigated the phenotype of epitope-specific and epitope-nonspecific CD8+ T cells.  We found 
similar patterns of phenotypes in both KS-negative and KS-positive subjects over time for both 
virus-specific and virus-nonspecific CD8+ T cells (Figure 11A-C).  Lowest levels of cells were 
found for naive and central memory cells, with higher levels of effector memory and terminally 
differentiated T cells.  Over time, levels of effector memory T cells increased, while terminally 
differentiated T cells decreased.  Although similar patterns were evident for HHV-8, CMV and 
HIV-1 specific cells, levels of terminally differentiated cells specific for HHV-8 (first column) 
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and CMV (second column) were initially higher than HIV-1 specific (third column) cells, while 
effector memory cells specific for HIV-1 were initially higher compared to the other viruses.  
Levels of naive and central memory cells were found at higher levels for virus-nonspecific cells 
(last column) compared to the virus-specific cells.   
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Figure 11. CD8 T cell phenotypes of virus-specific and non-specific cells 
MACS subjects were used as described in Figure 9.  Epitope-specific and epitope-nonspecific cells as defined by 
multimers were stained for phenotype markers. Mean (±SE) levels of each phenotype are shown for HIV-/HHV8+ 
(A, n=4), HIV+/HHV8+/KS- (B, n=10) and HIV+/HHV8+/KS+ (C, n=5) subjects over time for HHV-8-specific 
(first column), CMV-specific (second column), HIV-1-specific (third column) and epitope-negative (last column) 
CD8+ T cells.  Overall means compared by group are shown for HHV-8 epitope-specific cells that are naïve (D), 
effector memory (E), central memory (F) and terminally differentiated (G). 
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When comparing phenotypes of HHV-8-specific T cells among groups, the 
HIV+/HHV8+/KS- group had the highest levels of naive (Figure 11D) and effector memory 
(Figure 11E) cells, while the HIV-/HHV8+ group had the lowest levels.  Similar levels of central 
memory cells were evident in all groups, although levels were initially highest in the 
HIV+/HHV8+/KS+ group (Figure 11F).  For terminally differentiated cells, highest levels were 
in the HIV-/HHV8+ group, and lowest levels in the HIV+/HHV8+/KS- group (Figure 11G).   
Overall, these data show similar patterns of CD8+ T cell phenotypes for both virus-
specific and non-virus-specific cells. However, the data on non-epitope-specific T cells suggest 
that this is an effect of aging over the years of the study. 
3.3.3 Numbers of circulating Treg over many years prior to KS 
While we have shown that both monofunctional and polyfunctional CD8+ T cells specific for 
HHV-8 lytic and latency proteins are present in HHV-8 seropositive individuals, these T cell 
responses are relatively non-robust compared to other herpesviruses (135, 244).  This suggests 
that either the number and/or functional capacity of circulating anti-HHV-8 T cells is low.  
However, we found these CD8+ T cells are present in seropositve individuals (Figure 10).  This 
led us to investigate if HHV-8-specific CD8+ T cells are functionally down-regulated by Treg. 
In HIV-/HHV8- (Figure 12A), HIV-/HHV8+ (Figure 12B) and HIV+/HHV8+/KS- 
(Figure 12C) subjects, a low percentage of Treg was present that remained stable over time.  In 
HIV+/HHV8+/KS+ subjects (Figure 12D), a low percentage of Treg was present that began to 
increase 2-4 years prior to KS, which continued to increase within a year of KS.  Higher 
percentages of CD8+ compared to CD4+ T cells were present in HIV-1 seropositive subjects 
(Figure 12C-D).   
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Figure 12. Numbers of circulating Tregs over many years prior to KS 
MACS subjects were used as described in Figure 9. Mean (±SE) CD4+ T cell, CD8+ T cell and Treg percentages 
were determined by flow cytometry for HIV-/HHV8- (A, n=3), HIV-/HHV8+ (B, n=4), HIV+/HHV8+/KS- (C, 
n=10) and HIV+/HHV8+/KS+ (D, n=5) subjects over time.  Overall means compared by group are shown for CD4+ 
T cells (E), CD8+ T cells (F) and Treg (G).  (*= p<0.05 by ANOVA) 
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When comparing T cell percentages among groups, the lowest CD4+ T cell percentages 
were present in the KS-positive group, with significantly lower levels within a year of KS 
development (p=0.012) (Figure 12E).  CD8+ T cell percentages were significantly different as 
early as 4-6 years prior to KS (p<0.001) that persisted through KS development (p<0.001 at both 
2-4 and 0-1) (Figure 12F).  Levels of Treg began to increase in KS-positive subjects 2-4 years 
prior to KS, with significantly higher levels compared to the non-KS groups within a year of KS 
diagnosis (p=0.021) (Figure 12G).  Taken together, these data suggest that Treg could play a role 
in KS development as their numbers increase in the years leading to KS. 
3.3.4 Effect of Treg depletion on anti-HHV-8 CD8+ T cell responses 
We initially investigated the effect of Treg on anti-HHV-8 T cell responses using healthy, HHV-
8 seropositive individuals using single peptides from HHV-8, CMV and FLU.  As we used DC-
enhanced, 7 day cultures in our previous studies (135), we first compared these cultures with 
standard, overnight cultures in an ELISPOT assay.  Responses of PBMC cultured with peptide 
were compared to responses of PBMC that were depleted of Treg prior to culture with peptide in 
an ELISPOT assay.  We found that we were able to detect responses against HHV-8 epitopes 
when we removed Treg in standard, overnight cultures (see supplemental figures in Appendix B, 
Figure 20).  Based on these results and due to large cell numbers required in DC-enhanced 
cultures, we used standard, overnight cultures in further studies.  We next verified these 
overnight Treg depletion results in additional healthy, HHV-8 seropositive subjects.  We found 
that removal of Treg enhanced anti-HHV-8 T cell responses in healthy seropositive, but not 
seronegative, subjects (see supplemental figures in Appendix B, Figure 21).  Therefore, we next 
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examined Treg function in MACS subjects over many years prior to KS development.   Pools of 
HHV-8 latency peptides, HHV-8 lytic peptides, CEF peptides and HIV-1 peptides were used.   
 We found that removal of Treg from PBMC enhanced IFN-γ production in all subject 
groups and for all peptide pools over many years (Figure 13A-D).  We confirmed that this effect 
was not attributable to an activation of T cells during the bead and column depletion method, or 
to a proportional increase in number of CD8+ T cells after removal of Treg (see supplemental 
figures in Appendix B, Figure 22).  Differences for PBMC compared to PBMC depleted of Treg 
were significant in the HIV-/HHV8+ group for the HHV-8 lytic pool at 6-8 years (p=0.012) and 
the CEF pool at 0-1 year (p=0.029) (Figure 13B).  Differences were significant in the 
HIV+/HHV8+/KS- group at 4-6 and 0-1 years for both the HHV-8 latency (p=0.028 for 4-6 and 
p=0.021 for 0-1) and lytic pools (p=0.005 for 4-6 and p=0.014 for 0-1) (Figure 13C).  
Differences in this group were also significant at 8-12 (p=0.011) and 2-4 years (p<0.001) for the 
CEF pool and 4-6 years (p=0.008) for the HIV-1 pool (Figure 13C).  For the HIV+/HHV8+/KS+ 
group, differences were significant 4-6 years prior to KS development for both the HHV-8 
latency (p=0.022) and lytic pools (p=0.038) (Figure 13D).   
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Figure 13. Effect of Treg depletion on anti-HHV-8 CD8 T cell responses 
MACS subjects were used as described in Figure 9.  PBMC or PBMC depleted of Treg by a magnetic bead 
depletion system were cultured with an HHV-8 latency peptide pool, an HHV-8 lytic peptide pool, a CEF peptide 
pool or an HIV-1 peptide pool overnight in a standard IFN-γ ELISPOT assay.  Responses of cells cultured with 
medium alone were subtracted from peptide-induced responses to give net number of spots produced per million 
cells.  Net mean (±SE) responses are shown for HIV-/HHV8- (A, n=3), HIV-/HHV8+ (B, n=4), HIV+/HHV8+/KS- 
(C, n=10) and HIV+/HHV8+/KS+ (D, n=5) subjects over time.  Responses for HHV-8 latency and lytic pools are 
displayed in the left column, and CEF and HIV-1 pools are in the right column.  Overall means from all time points 
combined compared by groups are shown for the HHV-8 latency and lytic pools (E).  (*= p<0.05 by t-test) 
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Averaged over all time points of study, responses for Treg depleted samples were 
significantly enhanced for HHV-8 latency and lytic pools compared to PBMC for HIV-/HHV8+ 
(p=0.044 for latency and p=0.011 for lytic), HIV+/HHV8+/KS- (p<0.001 for both latency and 
lytic) and HIV+/HHV8+/KS+ (p=0.002 for latency and p=0.007 for lytic) groups (Figre 13E).  
Additionally, IFN-γ production was higher in response to the HHV-8 lytic pool compared to the 
HHV-8 latency pool (Figure 13E).  When comparing between groups, overall responses as well 
as Treg enhancements were greatest in the HIV-/HHV8+ group and lowest in the 
HIV+/HHV8+/KS+ group (Figure 13E).   
Overall, these data suggest that there is a functional down-regulation of anti-HHV-8 
CD8+ T cell responses by Treg, which is most evident in HIV-1 seronegative individuals. 
3.3.5 Levels of serum biomarkers within a year of KS development 
As differences in CD8+ T cells were found during progression to KS, we next examined levels of 
several biomarkers in the serum of MACS participants to investigate which factors may play a 
role in KS development.  We also looked for several Treg markers, including IL-10, TGF-β and 
IL-2, to provide insight into possible mechanisms by which Treg could be exerting their 
suppressive effects on HHV-8-specific CD8+ T cells.   
Significant differences between groups were not evident over many years prior to KS 
development (see supplemental figures in Appendix B, Figure 23).  We found the greatest 
differences between groups for these markers within a year of KS diagnosis (Figure 14).  For the 
markers present at the lowest levels, notable differences were found in IL-10, IFN-γ, IL-8, TNF-
α and MIP-1α (Figure 14A).  Higher levels of IL-10 and TNF-α were found in subjects co-
infected with HIV-1 and HHV-8 compared to those infected with only HHV-8 or seronegative 
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for both viruses.  Levels of IFN-γ, IL-8 and MIP-1α were higher the KS-positive group 
compared to those without KS.  For markers found at higher levels, differences were evident for 
VEGF (Figure 14B).  This marker was found at higher levels in the KS-positive group compared 
to the KS-negative groups.  While TGF-β was found at the highest levels, differences were not as 
evident between groups (Figure 14C).   
As B cells are one of the main targets of the virus, we also looked for a subset of these 
markers in B cells from KS patients.  Along with elevated levels in the serum, we found that B 
cells from KS cases had elevated RNA levels of IL-6, MIP-1α, IL-8 and VEGF compared to 
non-KS controls (see Appendix D).  Taken together, these data show that several biomarkers are 
increased at KS development. 
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Figure 14. Levels of serum biomarkers within a year of KS development 
Serum samples from MACS subjects were tested for the presence of biomarkers at KS using an 
electrochemiluminescence MSD assay.  Mean (±SE) concentrations (pg/mL) are shown for HIV-/HHV8- (n=10), 
HIV-/HHV8+ (n=7), HIV+/HHV8+/KS- (n=10) and HIV+/HHV8+/KS+ (n=10) subjects within a year of KS 
development. 
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3.4 DISCUSSION 
There is need to develop effective prevention and treatment for HHV-8 infection and associated 
diseases, as KS continues to be the most common cancer among HIV-1-infected persons despite 
advances in ART  (48).  CD8+ T cell responses to HHV-8 lytic and latency proteins could play a 
major role in controlling HHV-8 infection to prevent KS (17, 93).  To address this, a greater 
understanding of the immunopathogenesis of HHV-8 infection is needed.  We therefore 
performed longitudinal immunologic studies of MACS subjects who did and did not develop KS.   
Our most striking finding is that based on multiparameter immunologic assessments, 
HHV-8-specific CD8+ T cell immunity was lower beginning up to 12 years prior to diagnosis of 
KS in cases compared to those who did not develop KS.  This was evident in lower numbers of 
HHV-8 multimer-specific CD8+ T cells and less CD8+ T cell IFN-γ production specific for 
HHV-8 lytic and latency proteins. The basis of this profound immune dysfunction so early in 
HHV-8/HIV-1 co-infection is unclear.  There is no clear evidence for a genetic predisposition to 
HIV-1-associated KS.  Notably our study subjects were all HLA A*0201 due to the availability 
of HHV-8 immunodominant T cell epitopes associated with this MHC class I allele (202).   
Although very intriguing, most studies to date regarding the presence, frequency and 
phenotype of HHV-8 specific T cells in HHV-8 negative, HHV-8 infected and HHV-8/HIV-1 
co-infected persons are primarily cross sectional.  This lacks the power of more revealing, multi-
dimensional longitudinal analyses of anti-HHV-8 T cell responses.  In support of this, it was  
recently demonstrated that a decline in the quality of HIV-1-specific CD4+ and CD8+ T cells 
during HIV-1 infection, including functional cytokine production and a shift toward a memory 
cell phenotype, occurred over a 7 year period (58).  This evidence supports the need for 
longitudinal studies focusing on the reactivity of CD8+ T cells to HHV-8 lytic and latency 
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proteins in those individuals that control infection versus those who develop KS.  Therefore, we 
used MACS participants in such longitudinal studies to provide insight on the role of these 
effector responses and how they contribute to the prevention of KS. 
 In this study, we observed lower T cell counts and higher HIV-1 and HHV-8 viral loads 
in MACS subjects who developed KS.  We found the highest levels of HHV-8 epitope-specific 
CD8+ T cells in healthy, HHV-8 seropositive subjects who were not infected with HIV-1.  Over 
many years prior to KS, significantly lower levels of HHV-8-specific T cells were evident in the 
cases, which suggests that these CD8+ T cells specific for HHV-8 lytic and latency proteins are 
important in controlling infection to prevent disease.  In the KS cases, HHV-8-specific CD8+ T 
cells were lower even at the first visit approximately 10 years prior to disease development, 
indicating a very early suppressive effect on HHV-8 T cell responses.  While CD8+ T cell 
responses to HHV-8 were low many years prior to KS, we did not find an association with 
increases in HHV-8 plasma viral load.  We only found increases in HHV-8 in plasma within a 
year of KS diagnosis, which suggests that there may be additional factors along with CD8+ T 
cells that affect development of disease.  Furthermore, we found lower levels and less functional 
reactivity for  HHV-8-specific CD8+ T cells in all groups compared to CMV or HIV-1-specific 
cells.  This trend has also been found in other studies (93, 244), and could be related to the 
greater viral load of CMV and HIV-1 in persistently infected individuals, with more turnover of 
viral antigen that maintains a greater level of memory cytotoxic T lymphocyte precursors.   
In this study, all subjects were seroprevalent for both HHV-8 and HIV-1 upon study 
entry.  In future studies, we plan to include individuals who seroconverted to the viruses after 
study entry, which will provide insight about these responses during primary infection.  This will 
also allow us to further investigate these responses when HHV-8 infection occurs both before 
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and after HIV-1 co-infection.  In future studies, we also plan to include a subset of longitudinal 
visits in these subjects post-ART initiation, as the visits used in this study were all pre-ART.  
This will provide further insight on the effect of ART on anti-HHV-8 CD8+ T cell responses.   
 T cell responses to HHV-8 are likely directed against different lytic and latency proteins 
at different stages of infection and disease, similar to EBV-associated diseases (90).  During 
EBV infection, the hierarchy of CD8+ T cell reactivity to immunodominant epitopes is related to 
a lower expression of latency proteins compared to lytic proteins in infected cells (185).  During 
mononucleosis, a primary symptomatic infection of EBV, both lytic and latent EBV-specific T 
cells are present, but responses to lytic epitopes tend to be stronger (149).  This trend towards 
lytic responses is also evident in healthy, EBV seropositive individuals (105).  Similarly, CD8+ T 
cell responses to HHV-8 have been found to be directed more towards lytic compared to latency 
antigens (200, 201).  One recent study found that virus-specific T cells against LANA-1 in 
classic KS patients were associated with persistent KS, while K8.1-specific T cells were 
inversely correlated with KS occurrence (8).  Another study reported a novel late-lytic 
glycoprotein ORF28-P29 epitope that was recognized in 7% of HIV+/HHV8+ individuals (201), 
compared to an immunodominant HLA A*0201 late-lytic glycoprotein K8.1 epitope recognized 
in 71% (27).  In the present study, we have found that both the frequency and function, through 
multimer staining and ELISPOT assays, respectively, tend to be greater for the lytic epitopes in 
gB and K8.1 than the latency epitopes in LANA-1 and K12 both in the presence and absence of 
HIV-1 co-infection.  
 Antigen-specific CD8+ T cells occupy a lineage of naive and memory compartments that 
are involved in the expansion, effector and contraction phases of the CD8+ T cell immune 
response (96).  The naive, central memory, effector memory and terminally differentiated 
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phenotypes can be classified based on the expression of surface markers related to migration and 
differentiation.  The phenotype of CD8+ T cells likely plays a role in controlling infection to 
prevent disease.  In support of this, patients with MCD, another malignancy associated with 
HHV-8  infection, were found to have more cells with a late memory phenotype, compared to 
seropositive, healthy controls who had more cells with an early and intermediate phenotype (94).  
Interestingly, this MCD study found that HHV-8 viral loads were negatively correlated with 
early and intermediate effector memory cells and that the more differentiated T cell phenotype is 
associated with disease, rather than a loss of HHV-8 specific CD8+ T cells.  In one study of KS 
patients, those who controlled KS had greater percentages of HHV-8-specific terminally 
differentiated cells, while those who did not control KS had more effector memory cells (128).  
Another HHV-8 study found that the phenotype for CD8+ T cells specific for an HHV-8 epitope 
consisted mainly of effector memory cells, and also notable levels of terminally differentiated 
cells (201).  In regards to other virus-specific cells, the phenotype of HIV-1-specific cells tends 
to consist of higher levels of effector memory cells, while CMV-specific cells are mainly 
terminally differentiated (96).  In our study, we found similar patterns of phenotypes for HHV-8, 
CMV and HIV-1 specific T cells, as well as for epitope nonspecific cells, in the presence and 
absence of HIV-1 co-infection and for both KS-negative and KS-positive subjects.  As this study 
looked at responses over many years, the patterns in phenotypes may be an effect of aging, 
which alters the phenotype of T cell subsets (79). 
 Despite the presence of CD8+ T cells at a relatively high frequency in HHV-8 
seropositive subjects, the immune response to HHV-8 epitopes was found to be very low as 
measured by IFN-γ ELISPOT assays.  Therefore, it is possible that HHV-8-specific immune 
responses are down-regulated by Treg, which are a CD4+ T cell subset that function to maintain 
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peripheral tolerance and are also capable of immune suppression (151).  These cells are 
beneficial in preventing autoimmunity and tissue damage, but can also inhibit immunity needed 
to resolve infection and prevent disease.  Treg alter the immune response to many viruses, 
including EBV and HIV-1.  For example, in patients with Hodgkins lymphoma, Treg 
accumulated at tumor sites and those patients with higher Treg ratios had shorter disease-free 
survival (154, 209).  Additionally, in these patients, increases in Treg numbers were associated 
with decreases in EBV-specific CD8+ T cell IFN-γ production (155).  In patients with 
nasopharyngeal carcinoma, large numbers of Treg are found both at the tumor site and in 
circulation (132, 140).  During HIV-1 infection, HIV-1 specific CD8+ T cell responses and 
cytolytic activity are suppressed by Treg (121), and an increased Treg frequency negatively 
affected CD8+ T cell polyfunctionality, which was restored with Treg depletion (152).   
To our knowledge, this study is the first to explore Treg in relation to HHV-8 infection 
and disease development.  Interestingly, we found an increase in Treg frequency in KS cases 
compared to controls, which could mean that these cells are contributing to disease development 
through immune modulation.  We found that depletion of Treg significantly increased HHV-8-
specific IFN-γ  responses in HHV-8 seropositive subjects, which was evident to a greater extent 
in HHV-8 seropositive, HIV-1 seronegative subjects.  While this effect was present in all 
subjects, it was less apparent during HIV-1 co-infection without KS, and the lowest in magnitude 
for those that developed KS.  Of note, responses were only detected in HIV-1 seropositive, 
HHV-8 seropositive KS-negative and KS-positive subjects when Treg were depleted from the 
PBMC samples.  Additionally, this effect was evident even during early infection many years 
prior to the development of KS.  Compared to HHV-8, responses to the CEF pool as well as to 
HIV-1 were greater in both the presence and absence of Treg.  We also plan to look at the effect 
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of Treg in seroconvertors to investigate these responses during primary infection as well as 
HHV-8 infection before and after HIV-1 infection.  We also plan to examine Treg at post-ART 
visits to investigate if therapy alters the effects of Treg on anti-HHV-8 T cell responses.  In 
addition, we also plan to look at these responses in ICS assays to provide further insight on the 
quality of response through the inclusion of more immune mediators. 
 Treg are known to have several mechanisms of suppression, including production of 
inhibitory cytokines such as IL-10 and TGF-β.  Therefore, we also looked for these factors in the 
serum of the study subjects.  However, significant differences in these markers were not evident 
at KS development for cases compared to controls.  It is possible that Treg in KS patients 
function through other mechanisms, such as use of inhibitory receptors, cytolytic activity or 
metabolic disruption (151).  The exact role and mechanism of Treg during HHV-8 infection 
needs to be further investigated as these cells could play an important role in disease 
development.  As we did not see major increases in responses when Treg were removed in KS-
positive subjects yet we found a significant increase in Treg numbers prior to KS, it is also likely 
that other mechanisms of suppression play a role in the inability of CD8+ T cells to control 
HHV-8 infection.  For example, PD-1 expression was found to be increased on HIV-1-specific 
CD8+ T cells, which was associated with an impairment of function through a reduced ability to 
produce cytokines and effector molecules as well as decreased proliferation (234).  This also 
could be important during HHV-8 and HIV-1 co-infection and needs to be examined in future 
studies. 
  In addition to the levels of CD8+ and CD4+ T cells, cytokines and chemokines produced 
by T cells as well as other types of cells, such as APC, likely play a crucial role in disease 
development.  Inflammatory changes occur early in KS, prior to the detection of the cancer 
 85 
(162).  KS tumors are known to be rich in inflammatory cell infiltrates, including CD8+ T cells, 
B cells, macrophages and monocytes (166).  These infiltrating cells produce large amounts of 
proinflammatory cytokines (e.g., IFN-γ, IL-1β, TNF-α and IL-6), chemokines (e.g., IL-8), and 
growth factors (e.g.,VEGF) (70, 75, 166, 186).  We therefore examined serum samples for the 
presence of several biomarkers over many years prior to KS development, but found the greatest 
differences between cases and controls within a year prior to KS.  Increases in IFN-γ, IL-8, TNF-
α, MIP-1α and VEGF were noted in the cases compared to controls.  These factors may 
contribute to creating an environment that promotes the spread of HHV-8 infection and 
subsequent KS development. 
 In conclusion, we have revealed several important differences in the immune response to 
HHV-8 infection in KS cases compared to those that did not develop KS over many years 
leading to disease development.  Specifically, the frequency of circulating CD8+ T cells specific 
for both HHV-8 lytic and latency proteins was lower over many years in the cases prior to KS.  
These cells have a predominantly effector memory and terminally differentiated phenotype.  
Numbers of Treg increased in the cases prior to the development of KS, and these cells suppress 
HHV-8-specific T cell responses.  The present study supports the hypothesis that T cell 
responses, in frequency, quality and magnitude, are essential for control of HHV-8 infection to 
prevent development of disease. 
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4.0  CONCLUSION 
Professional APC are critically important in the recognition of an invading pathogen and 
presentation of antigens to the T cell-mediated arm of immunity.  HHV-8 targets these APC for 
infection, altering their cytokine profiles, manipulating their surface expression of MHC 
molecules and altering their ability to activate HHV-8-specific T cells.  HHV-8 infection of 
professional APC could demonstrate an evolutionary mechanism to establish viral latency in cell 
types responsible for initiating T and B cell adaptive immune responses.  Subsequently, T cell 
responses to HHV-8 antigens are not very robust as compared to the other human 
gammaherpesvirus, EBV.  In some instances, APC support lytic HHV-8 infection, and the 
replication cycles directly affects viral pathogenesis and progression to KS and certain B cell 
lymphomas.  Given that KS lesions are common in the skin and mucosa which are heavily 
populated with APC, the interaction of APC with HHV-8 and the subsequent effect on T cell 
responses is of central importance.  As KS continues to be the most common cancer associated 
with HIV-1 infection, understanding the immunopathogenesis of this virus to develop treatments 
and vaccines for HHV-8-associated diseases has significant public health implications. 
To succeed, a pathogen must be able to evade immune surveillance.  HHV-8 infects APC 
and has revealed two distinct replication patterns of HHV-8 in APC, i.e., non-productive and 
productive, which could have direct consequences on viral pathogenesis.  The direct effect of 
HHV-8 infection of professional APC and its indirect effect on T cell control of infection need to 
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be tied together in a more revealing fashion to define the magnitude and breadth of T cell 
responses to HHV-8 antigens.  It is likely that T cell responses, in both quality and magnitude, 
are essential for control of HHV-8 infection.  Although evident in HHV-8 infection, it is not 
clear whether polyfunctional T cells are required to control progression of associated diseases.  
Furthermore, T cell responses to HHV-8 antigens are not very robust as compared to EBV and 
CMV.  This dampened immune response could be related to down-regulation by Treg.  A 
delicate balance exists between protective immunity involving cytokine and chemokine 
production by host cells, and virus-driven induction of cytokines and chemokines that aid in the 
dissemination and spread of infection and mediate pathogenesis.  The role of each cytokine and 
chemokine in HHV-8 infection and KS likely varies depending on their quantity and origin of 
production.  Several of the mediators that are essential to the immune response and activation of 
lymphocytes can exacerbate infection and cause clinical symptoms when over produced in 
response to HHV-8 infection.   
My studies have provided valuable, novel insight into the immune response to HHV-8.  
This is important as the immunity to HHV-8 is much less well defined than to EBV, yet HHV-8 
has a significant public health impact, especially on the HIV-1-infected population.  In initial 
studies, I used healthy, HHV-8 seropositive subjects to explore CD8+ T cell responses to HHV-8.  
I identified 10 novel, HLA A*0201 epitopes in two lytic and two latency proteins.  A major 
limitation in studying HHV-8 immune responses to date is lack of known epitopes in viral 
proteins, so this work greatly increases the number of epitopes that can be used in future studies 
of the complex immune response to this virus.  In these healthy subjects, I found that lytic and 
latency epitopes induced various combinations of both monofunctional and polyfunctional T cell 
responses.  Polyfunctional responses have been shown to be crucial in control of other viruses, 
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including HIV-1.  This was the first study to show the presence of polyfunctional T cells specific 
for HHV-8 lytic and latency epitopes in healthy, HHV-8 seropositive individuals.  This suggests 
that response quality, as examined through polyfunctional T cells producing multiple immune 
mediators to respond against the virus, is important in controlling the spread of HHV-8 infection.  
While the immune responses to this virus are relatively non-robust, this was also the first study 
to directly show the presence of CD8+ T cells specific for lytic and latency proteins in the blood 
of healthy, HHV-8 seropositive individuals controlling infection.  Overall, these studies in 
healthy, HHV-8 seropositive individuals are important because they provide insight on the 
immune responses to regions of the virus that may be critical in controlling the spread of 
infection and disease development. 
The development of effective treatments and vaccines for KS requires an understanding 
of the differences in immune responses for those that did and did not develop the disease.  My 
next study therefore involved MACS participants who were co-infected with HIV-1 and HHV-8 
that did and did not develop KS.  A major strength of the study was the longitudinal aspect in 
examining responses over many years prior to disease, as the majority of the studies completed 
to date have been cross-sectional.  In fact, this was the first longitudinal comprehensive 
investigation of CD8+ T cell responses to HHV-8 lytic and latency proteins and their relation to 
progression of HHV-8 infection and development of KS in homosexual men  in the MACS.  
Higher levels of cells specific for HHV-8 lytic epitopes were evident compared to cells specific 
for HHV-8 latency epitopes.  This may be due to higher levels of lytic proteins present during 
infection as compared to latency proteins, and cells specific for lytic epitopes may be important 
in controlling the spread of infection when the virus is reactivated.  Overall, I found highest 
levels of CD8+ T cells specific for HHV-8 lytic and latency proteins in subjects only infected 
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with HHV-8, and lower levels in those co-infected with HHV-8 and HIV-1.  Notably, lowest 
levels of CD8+ T cells were evident in KS patients, even many years prior to disease 
development.  This suggests that CD8+ T cells are important in preventing KS development 
during HIV-1 and HHV-8 co-infection, as levels of these cells were higher in those that did not 
develop disease and may represent the effective control of infection to prevent KS.  
I also investigated the effect of Treg on CD8+ T cell responses to HHV-8 proteins.  
Removal of Treg showed that the relatively low functional reactivity of CD8+ T cells to HHV-8 
in healthy, HHV-8 seropositive individuals was due to the immunosuppressive effects of Treg, as 
responses to HHV-8 proteins were enhanced following removal of Treg.  This is the first 
evidence that Treg down-regulate anti-HHV-8 T cell responses.  This effect was also present in 
those co-infected with HIV-1 and HHV-8 that did and did not develop KS, but was most evident 
in those only infected with HHV-8.  Notably, numbers of Treg significantly increased prior to 
KS development, suggesting that they may play a role in promoting disease development through 
immune modulation.  However, as removal of Treg in KS subjects resulted in the lowest levels 
of enhancement despite the highest Treg numbers, it is likely that other mechanisms of immune 
regulation are also important during KS development.  Overall, these data in MACS participants 
support that T cell responses, in frequency, magnitude and quality, specific for HHV-8 lytic and 
latency proteins are centrally involved in controlling HHV-8 infection to prevent KS 
development (see model in Figure 15).   
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Figure 15. Hypothetical role of anti-HHV-8 T cells in control of HHV-8 infection 
We hypothesized that in immunocompetent individuals, monofunctional and polyfunctional CD8+ T cells specific 
for HHV-8 lytic and latency proteins can kill cells that are infected by the virus to control the spread of infection and 
prevent disease development.  However, in those that are immunosuppressed, such as during HIV-1 co-infection, 
these anti-HHV-8-specific CD8+ T cells might not be functioning properly, which leads to the spread of infected 
cells and disease development, such as KS.  Furthermore, Treg may play a role in modulating these CD8+ T cell 
responses.  Overall, the data of my project support this initial hypothesis, with my findings highlighted in the yellow 
boxes. 
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To provide further insight into these responses, future studies should include subjects that 
seroconverted to these viruses after study entry to examine responses during primary infection.  
Additionally, subjects should be included that were infected with HIV-1 prior to and after HHV-
8 to look at the impact of the order and timing of infection.  As viral lytic reactivation from 
latency could be affecting these responses, longitudinal HHV-8 antibody titers should be 
examined to determine if they correlate with responses of CD8+ T cell during disease 
development.  Additionally, correlating HHV-8 antibody titers to Treg levels and responses may 
provide insight as to whether HHV-8 infection induces Treg.  CD8+ T cell and Treg responses 
should also be examined in subjects post-ART to explore the impact of therapy on these 
responses.  Polyfunctional responses for additional immune mediators should also be included in 
future studies to further investigate the quality of CD8+ T cell responses during the progression 
to KS, as well as the effect of Treg on the quality of immune responses.  Levels of markers of 
immune activation, such as CD38 and HLA-DR, should be examined to determine the effect of 
immune activation on CD8+ T cell and Treg responses.  Another future direction of this project 
should be to look at other possible mechanisms that Treg may be using to suppress anti-HHV-8 
T cell responses, such as through inhibitory receptors or metabolic disruption.  Additionally, as 
Tregs are likely not the only factor influencing disease development, other suppressive factors 
that may be important in disease development should be explored, such as PD-1. 
Taken together, the work generated throughout this project has important public health 
implications.  We have revealed novel data regarding the immune response to HHV-8 in healthy, 
seropositive individuals controlling infection, as well as highlighted some of the differences in 
responses between those that are co-infected with HHV-8 and HIV-1 who did and did not 
develop cancer.  These studies therefore help to provide insight as to why certain individuals 
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develop KS while others do not develop the cancer, so it is possible that these protective immune 
responses could be enhanced through therapies and vaccines.  Understanding both the 
immunopathogenesis of HHV-8 infection and the immune responses that control infection to 
prevent disease progression are essential for the development of therapeutic and preventative 
vaccine strategies.  If successful, effective vaccines to prevent HHV-8 infection and treatments 
for KS could improve the lives of many people around the world by decreasing the burden of the 
most common cancer currently associated with HIV-1 infection. 
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APPENDIX A. ABBREVIATIONS 
aa: amino acids 
AIDS: acquired immune deficiency syndrome 
ANOVA: analysis of variance 
APC: antigen presenting cells 
ART: antiretroviral therapy 
BCBL: body cavity based lymphoma cells  
CCL: chemokine ligand 
CD40L: CD40 ligand 
CIITA: class II transactivator 
CMV: cytomegalovirus 
CTL: cytotoxic T lymphocyte 
DC: dendritic cells 
DC-SIGN: DC-specific ICAM-3 grabbing nonintegrin 
Dox: doxycycline 
EBV: Epstein Barr virus 
EDTA: ethylenediaminetetraacetic acid 
ELISPOT: enzyme-linked immunosorbent spot 
ERK: extracellular signal-regulated kinase 
FACS: fluorescence-activated cell sorting 
FCS: fetal calf serum 
FGF: fibroblastic growth factor 
FITC: fluorescein isothiocyanate 
FLICE: FADD-like interferon converting enzyme  
gB: glycoprotein B 
GM-CSF: granulocyte-monocyte colony-stimulating factor 
GPCR: G-protein coupled receptor 
h: hours 
HGF/ SF: hepatocyte growth factor/ scatter factor 
HHV-8: human herpesvirus 8 
HIV-1: human immunodeficiency virus 1 
HLA: human leukocyte antigen 
ICAM: intercellular adhesion molecule 
ICS: intracellular staining 
iDDC: interstitial-dermal DC 
IFN: interferon 
Ig: immunoglobulin 
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IL: interleukin 
IP: interferon gamma-induced protein 
IRF: interferon regulatory factor 
KS: Kaposi’s sarcoma 
KSHV: Kaposi’s sarcoma associated herpesvirus 
LANA: latency associated nuclear antigen 
LC: Langerhans cells  
LCL: lymphoblastoid cell line 
mAb: monoclonal antibody 
MACS: Multicenter AIDS Cohort Study 
MAPK: mitogen activated protein kinase 
MCD: multicentric Castleman’s disease 
MCP: monocyte chemoattractant protein 
MDDC: monocyte-derived DC 
MDM: monocyte-derived macrophage 
MHC: major histocompatibility complex 
min: minutes 
MIP: macrophage inflammatory protein 
MIR: modulator of immune recognition 
MSD: Meso Scale Discovery 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells  
NIH: National Institutes of Health 
NK: natural killer 
ORF: open reading frame 
PBMC: peripheral blood mononuclear cells 
PBS: phosphate buffered saline 
PCR: polymerase chain reaction 
PD: programmed death 
pDC: plasmacytoid DC 
PE: phycoerythrin 
PEL: primary effusion lymphoma 
PerCP: peridinin chlorophyll protein 
PFA: paraformaldehyde 
PGE2: prostaglandin E2 
SE: standard error 
SOC: suppressor of cytokine signaling 
SPICE: simplified presentation of incredibly complex evaluations 
TCR: T cell receptor 
TGF: transforming growth factor 
Th: T helper 
TLR: Toll-like receptor 
TNF: tumor necrosis factor 
TPA: 12-O-tetradecanoylphorbol-13-acetate 
Treg: T regulatory cell 
VEGF: vascular endothelial growth factor 
vFLIP: viral FLICE inhibitory proteins 
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APPENDIX B. SUPPLEMENTAL FIGURES 
 
Figure 16. Medium and peptide concentration comparison 
PBMC were stimulated for one week with autologous, mature DC that were loaded with previously published HHV-
8 epitopes.  To compare assay conditions, we used AIM-V and RPMI supplemented with 10% FCS, with peptide 
concentrations of 2µg/ml and 5µg/ml.  IFN-γ production was measured by an ELISPOT assay, and the number of 
spots produced by cells without peptide was subtracted from spots produced by cells with peptide to give net values 
of spots.  Net responses are shown for a representative healthy, HHV-8 seropositive subject.   
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Figure 17. Comparison of DC-enhanced, 7 day and standard, overnight ELISPOT cultures 
PBMC were stimulated for one week with autologous, mature DC that were loaded with previously published HHV-
8 epitopes.  PBMC were also cultured overnight with peptide.  IFN-γ production was measured by an ELISPOT 
assay, and the number of spots produced by cells without peptide was subtracted from spots produced by cells with 
peptide to give net values of spots.  Net responses are shown for a representative healthy, HHV-8 seropositive 
subject.   
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Figure 18. ELISPOT responses a hotspot family using varying peptide concentrations 
PBMC were stimulated for one week with autologous, mature DC that were loaded with five different, 10-fold 
concentrations of peptide from a hotspot family.  IFN-γ production was measured by an ELISPOT assay, and the 
number of spots produced by cells without peptide was subtracted from spots produced by cells with peptide to give 
net values of spots.  Net responses are shown for a representative healthy, HHV-8 seropositive subject in response to 
a peptide family from gB.   
 
 
 
 
 
Figure 19. Multimer comparison of a pentamer and dextramer 
PBMC were stained with an MHC class I-peptide pentamer or dextramer complex specific a CMV epitope.  Results 
are shown for a representative healthy, HHV-8 seropositive subject. 
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Figure 20. Comparison of ELISPOT cultures with Treg depletion 
PBMC or PBMC depleted of Treg by a magnetic bead depletion system were stimulated for one week with 
autologous, mature DC that were loaded with HHV-8, CMV and FLU peptides (A).  PBMC or PBMC depleted of 
Treg were also cultured overnight with peptide (B).  IFN-γ production was measured by an ELISPOT assay, and the 
number of spots produced by cells without peptide was subtracted from spots produced by cells with peptide to give 
net values of spots.  Net responses are shown for a representative healthy, HHV-8 seropositive subject. 
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Figure 21. Effect of Treg depletion on anti-HHV-8 CD8 T cell responses in healthy subjects 
PBMC or PBMC depleted of Treg by a magnetic bead depletion system were cultured overnight with HHV-8, CMV 
and FLU peptides.  IFN-γ production was measured by a standard ELISPOT assay, and the number of spots 
produced by cells without peptide was subtracted from spots produced by cells with peptide to give net values of 
spots.  Net mean (±SE) responses are shown for three healthy, HHV-8 seronegative subjects (A) and five healthy, 
HHV-8 seropositive subjects (B). 
 
 
 
 
 101 
 
Figure 22. Treg depletion method comparison with staining 
PBMC, PBMC that were passed through the magnetic bead depletion column system but not depleted of Treg, or 
PBMC depleted of Treg were cultured overnight with HHV-8, CMV and FLU peptides.  IFN-γ production was 
measured by a standard ELISPOT assay, and the number of spots produced by cells without peptide was subtracted 
from spots produced by cells with peptide to give net values of spots.  Net responses are shown for a healthy, HHV-
8 seropositive subject.  These samples were also stained for the surface markers CD8, CD4 and CD25. 
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Figure 23. Levels of serum biomarkers over many years prior to KS 
Serum samples from MACS participants were tested for the presence of biomarkers using an 
electrochemiluminescence MSD assay. Mean (±SE) concentrations (pg/ml) are shown for HIV-/HHV8- (n=10), 
HIV-/HHV8+ (n=7), HIV+/HHV8+/KS- (n=10) and HIV+/HHV8+/KS+ (n=10) subjects over many years prior to 
KS diagnosis. 
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APPENDIX C. MACS SUBJECTS FOR LONGITUDINAL STUDY 
As described in chapter 3.0, we investigated the importance of CD8+ T cell responses and the 
role of Treg during the progression to KS using MACS subjects that did or did not develop the 
cancer.  We performed longitudinal studies over many years of study visits for 10 
HIV+/HHV8+/KS- and five HIV+/HHV8+/KS+ subjects.  We also included four HIV-
/HHV8+/KS- subjects to investigate the natural history of HHV-8 infection without the presence 
of HIV-1 co-infection.  As controls, we also included three HIV-/HHV8-/KS- subjects.  Graphs 
displaying the overall averages for each group are shown in the chapter above, and individual 
subject data are shown below. 
C.1 HIV-/HHV8-/KS- 
In three HIV-/HHV8-/KS- subjects (Figure 24), we measured blood T cell counts by flow 
cytometry (A), levels of HHV-8, CMV and HIV-1 epitope-specific CD8+ T cells by dextramer 
staining (B) and their phenotype by flow cytometry (C), frequency of Treg by flow cytometry 
(D) and IFN-γ ELISPOT responses to HHV-8, CEF and HIV-1 peptide pools using PBMC or 
PBMC that were depleted of Treg with a magnetic bead depletion system (E) over many years of 
study. 
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Figure 24. HIV-/HHV8-/KS- subjects 
 
 
C.2 HIV-/HHV8+/KS- 
In four HIV-/HHV8+/KS- subjects (Figure 25), we measured blood T cell counts by flow 
cytometry (A), HHV-8 plasma viral load by PCR (B), levels of HHV-8, CMV and HIV-1 
epitope-specific CD8+ T cells by dextramer staining (C) and their phenotype by flow cytometry 
(D), frequency of Treg by flow cytometry (E) and IFN-γ ELISPOT responses to HHV-8, CEF 
and HIV-1 peptide pools using PBMC or PBMC that were depleted of Treg with a magnetic 
bead depletion system (F) over many years of study. 
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Figure 25. HIV-/HHV8+/KS- subjects 
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C.3 HIV+/HHV8+/KS- 
In 10 HIV+/HHV8+/KS- subjects (Figure 26), we measured blood T cell counts by flow 
cytometry (A), HHV-8 and HIV-1 plasma viral load by PCR (B), levels of HHV-8, CMV and 
HIV-1 epitope-specific CD8+ T cells by dextramer staining (C) and their phenotype by flow 
cytometry (D), frequency of Treg by flow cytometry (E) and IFN-γ ELISPOT responses to 
HHV-8, CEF and HIV-1 peptide pools using PBMC or PBMC that were depleted of Treg with a 
magnetic bead depletion system (F) over many years of study. 
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Figure 26. HIV+/HHV8+/KS- subjects 
 
 
 
C.4 HIV+/HHV8+/KS+ 
In five HIV+/HHV8+/KS- subjects (Figure 27), we measured blood T cell counts by flow 
cytometry (A), HHV-8 and HIV-1 plasma viral load by PCR (B), levels of HHV-8, CMV and 
HIV-1 epitope-specific CD8+ T cells by dextramer staining (C) and their phenotype by flow 
cytometry (D), frequency of Treg by flow cytometry (E) and IFN-γ ELISPOT responses to 
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HHV-8, CEF and HIV-1 peptide pools using PBMC or PBMC that were depleted of Treg with a 
magnetic bead depletion system (F) over many years prior to the development of KS. 
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Figure 27. HIV+/HHV8+/KS+ subjects 
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APPENDIX D. IMMUNE MEDIATORS IN SERUM AND B CELLS DURING KS 
To further investigate the role that immune mediators play in HHV-8 disease development, we 
examined several mediators in additional MACS participants who were co-infected with HIV-1 
and HHV-8, and who did (cases) or did not (controls) develop KS.  Three visits were chosen, 
with one visit within a year of KS development in the cases and the corresponding visit in the 
controls, a second visit 2-5 and a third visit 6-10 years prior to KS.  Lower numbers of CD4+ T 
cells, and higher numbers of CD8+ and CD3+ T cells were present in KS cases compared to 
controls 2-5 years before KS development (i.e., diagnosis) (Figure 28A).  Plasma viral loads for 
HIV-1 (p=0.007) and HHV-8 were higher within the year prior to KS in cases (Figure 28B).  We 
noted a similar pattern of lower serum levels of IL-8, MIP-1α, MIP-1β and VEGF at 6-10 years 
pre-KS in cases, with a progressive increase in levels of these immune mediators in cases 2-5 
years pre-KS and within 1 year of KS (Figure 28C).  IL-8 and MIP-1α levels were nearly 2-fold 
higher and significantly increased (p=0.01 and 0.008, respectively) in KS cases within the year 
prior to KS.  Levels of MIP-1β and VEGF increased over time in the KS cases and decreased in 
the controls, with higher levels evident in the cases the year prior to KS.  TNF-α concentrations 
were higher at all time points in the KS cases compared to the controls.  Both TNF-α and VEGF 
approached significance (p=0.07) in KS cases.  IL-6 levels were slightly higher in the controls 
than cases over the total 6-10 years of follow-up.  Collectively, these data show that levels of IL-
8, TNF-α, MIP-1α, MIP-1β and VEGF, but not IL-6, are increased within a year of KS diagnosis. 
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Figure 28. T cell counts, viral loads and serum biomarkers in MACS participants 
HIV-positive, HHV-8-positive, KS-negative (controls) and HIV-positive, HHV-8-positive, KS-positive (cases) 
subjects were selected from the Pittsburgh MACS.  CD3, CD4 and CD8 T cell counts at each visit were determined 
by flow cytometry (A, mean±SE., N=10 at years 2-10 prior, N=15 at years 0-1 prior, per group).  Plasma HHV-8 
and HIV-1 viral loads at each visit were determined by PCR (B, mean±SE., N=10 at years 2-10 prior, N=15 at years 
0-1 prior, per group).  For each visit, frozen serum samples were thawed and concentrations of TNF-α, IL-8, MIP-
1α, IL-6, MIP-1β and VEGF were determined using an electrochemiluminescence MSD assay (C, mean±SE., N=10 
at years 2-10 prior, N=15 at years 0-1 prior, per group).  (*p<0.05 by t-test) 
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As B cells are a main target of HHV-8, we also determined whether B lymphocytes were 
producing these biomarkers.  B cells were purified from PBMC of two KS cases and two non-KS 
controls and assayed for viral DNA and immune mediator mRNA at 0-1 years prior to KS 
development.  As determined by PCR, both non-KS controls and one KS case had undetectable 
levels of HHV-8 in their CD19+ B cells, while one KS case had a viral load of 183,306 
copies/500,000 cells.  RNA was extracted and used in a PCR assay to determine mRNA 
expression of immune mediators.  Expression of IL-6, MIP-1α, IL-8 and VEGF mRNA was 
elevated in KS cases compared to controls, with 3.7, 1.9, 1.3 and 1.2-fold increases, respectively 
(Figure 29).  MIP-1β levels were similar among cases and controls, while TNF-α was enhanced 
in KS controls.  These data indicate that HHV-8 infected B cells produce more proinflammatory 
cytokines, chemokines and growth factors in HIV-1 infected individuals who are developing KS 
compared to those without KS. 
This appendix was modified from: Human Herpesvirus 8 Lytic Infection Induces 
Polyfunctional Memory and Naive B Lymphocyte Reactivity, submitted for publication, E. 
Knowlton, G. Rappocciolo, L. Lepone, S. Nadgir, A. Bulotta, S. Berendam, J. Li, T. Reinhart, F. 
Jenkins and C. Rinaldo. 
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Figure 29. mRNA expression in B cells from KS cases and controls 
CD19+ cells were isolated from PBMC of two HIV-positive, HHV-8-positive, KS-negative (controls) and two HIV-
positive, HHV-8-positive, KS-positive (cases) subjects from the Pittsburgh MACS at 0-1 years prior to KS 
development.  RNA was extracted and used in a real-time PCR assay to determine mRNA expression of immune 
mediators (mean±SE., N=2 per group). 
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